

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00	A1	(11) International Publication Number: WO 99/29728 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97) (71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).	(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES (57) Abstract The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see *generally* Coutinho, 1991, Immune System, *Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , γ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\gamma\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\gamma\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\gamma\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravec et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EB11-ligand chemokine	ELC	A8000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	A8000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chem kine Class	Chem kines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CX3C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clontech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogam et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, i.e., a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, Protein Research Foundation, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokine(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 *supra*)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1_{MSB} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{MSB}. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIB} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same does of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
42. The composition of claim 33, wherein the chemokine is a human chemokine.
43. The composition of claim 33, wherein the antigen is an HIV antigen.
44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.

46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6CKine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val	-24
	-20
	-15
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
	-10
	-5
	1
GGC GCC AAC ATG GAA GAC AGC AGC GTC TGC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr	
	5
	10
	15
CGT CTG CCC CTG CGC GTG GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
	20
	25
	30
	35
TGC CCG AGG CCT GGC GTG GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile	
	40
	45
	50
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
	55
	60
	65

FIG. 1A-1

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA 348
 Ser Gln

 GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408
 CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCAC TGCC 468
 ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCCTGCAGTC AGAGGGTCCT 528
 GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588
 GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
 CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTCTCCAA ACCCATACTA 708
 CACATCCAC TTCTGGGTCT TTGCCTGGGA TGTGCTGAC ACTCAGAAAG TCCCACCACC 768
 TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828
 CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCCTC TTAATAACCC TAGTCACAGT 888
 CTCCGCAGAT TCTTGGGATT TGGGGTTTT CTCCCCACC TCTCCACTAG TTGAGCCAAG 948

FIG. 1A-2

GTTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCC	1008
TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAAC TAATGTCCCT	1068
CCCCCTCTCCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT	1128
GGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT	1188
CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTGCTC TTGTCACCCA CGCTGGAGTG	1248
CAATGGTGTG GTCTTGGCTT ATTGAAGCCT CTGCCTCCTG GGTTCAAAGTG ATTCTCTTGC	1308
CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCTCTGCTAC CACGCCCAGC TAATTTTGT	1368
ATTTTTAGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCCCTC	1428
AGGTAATCCG CCCACCTCAG CCTCCCCAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC	1488
CTGGCCCTCTT CCTCTCTCCC ACTGCCCCCC CCAACTTTT TTTTTTTTTT ATGGCAGGGT	1548
CTCACTCTGT CGCCCAGGCT GGAGTGCAGT GCGTGATCT CGGCTACTA CAACCTCGAC	1608
CTCCTGGGT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGT	1668

3/6

FIG. 1A-3

1728 TGCCACTACG GCTGGCTAAT TTTTGTATT TTAGTAGAGA CAGTTTCAC CATAATGGCC
1788 AGGCTGGTCT TGAACCTCCTG ACCTCAAGTG ATCCACCTTC CTTGTGCTCC CAAAGTGCTG
1848 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCCTAAT AGGAGACTCC
1908 TGTACCTTTC TTCGTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCTCAGG
1968 CTTTTTTTGG GTGGTCCTCC AACCTCCAAT ACCCAGGCCT GGCCTCTTCA GAGTACCCCC
2028 CATTCACACT TCCCTGCCTC CTTCTTAAA TAGCTGACAA TCAAATTCAT GCTATGGTGT
2088 GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG
2148 TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAATTT AGGAACGTG AGAGGGGGAC
2208 AAGGTGAAGC TTTCTTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC
2268 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG
2328 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGTCTATC TATGCCTTTC
2388 TGGCTGATTT TTGTAGAGAC GGGGTTTTC CATGTTACCC AGGCTGGTCT CAAACTCCTG

FIG. 1A-4

GGCTCAAGCG	ATCCTCCTGG	CTCAGCCTCC	CAAAGTGCTG	GGATTACAGG	CGTGAATCAC	2448
TGCGCCTGGC	TTCCCTCTTC	TCTTGAGAAA	TATTCTTTTC	ATACAGCAAG	TATGGGACAG	2508
CAGTGTCCTCA	GGTAAAGGAC	ATAAATGTTA	CAAGTGCTCG	GTCCTTTCTG	AGGAGGCTG	2568
GTGCCGCTCT	GCAGGGTATT	TGAACCTGTG	GAATTGGAGG	AGGCCATTTC	ACTCCCCTGAA	2628
CCCAGCCTGA	CAAATCACAG	TGAGAATGTT	CACCTTATAG	GCTTGCTGTG	GGGCTCAGGT	2688
TGAAAGTGTG	GGGAGTGACA	CTGCCCTAGGC	ATCCAGCTCA	GTGTCATCCA	GGGCCTGTGT	2748 ^{5/6}
CCCTCCCGAA	CCCAGGGTCA	ACCTGCCCTGC	CACAGGCACT	AGAAGGACGA	ATCTGCCCTAC	2808
TGCCCCATGAA	CGGGGCCCTC	AAGCGTCCTG	GGATCTCCTT	CTCCCCTCCTG	TCCTGTCCCTT	2868
GCCCCCTCAGG	ACTGCTGGAA	AATAAATCCT	TTAAAATAGT	AAAAAAAAAA	AAAAA	2923

FIG. 1A-5

FIG. 1A

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

6/6

Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Leu	Val	Val	Leu	Val	Leu	Leu	Ala
-24				-20					-15					-10	
Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu
			-5					1				5			
Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Arg
	10					15					20				
Val	Lys	His	Phe	Tyr	Tyr	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly
25				30					35					40	
Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Arg
				45					50					55	
Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	Ser	Gln			
				60				65							

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

(2) INFORMATION FOR SEQ ID NO:2:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION:

(X1) SEQUENCES DESCRIBED: SEQ IS NOT:

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines

Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA PRI 31-MAY-1997
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA, complete
 cds.
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
 Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska,R., Chantry,D., Raport,C.J., Sozzani,S., Allavena,P., Leviten,D., Mantovani,A. and Gray,P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska,R. and Gray,P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE, Bothell, WA 98021, USA
 FEATURES
 source Location/Qualifiers
 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQATALLVVLVLLAVALQATEAGFYGANMEDSVCCRDYVRYR
 LPLRVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQL"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacataca ggacagagca tggctcgctt acagactgca ctccctgggtg tctctgctct
 61 ccttgctgtg gcgcttcaag caactgaggg agggccctac ggcgccaaca tgggaagacag
 121 cgtctgctgc cgtgattacg tccgttaccg tctgccccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtggtggtg ctaaccttca gggataagga
 241 gatctgtgcc gatcccagag tgcccctgggt gaagatgatt ctcaataaagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctctccagg aaggctcagg agccctacct
 361 ccctgccatt atagctgttc ccgcccagaa gcctgtgcca actctctgca ttccttgatc
 421 tccatccctg tggctgtcac ccttggtcac ctccgtgtgt tcaactgcca ctccccctg
 481 accctcttaa cccatcctct gcctccctcc ctgcagtcag agggctctgt tcccatcagc
 541 gatccctctg cttaaacctt tccatgactc cccactgccc taagctgagg tcagctctccc
 601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
 661 ccttcatgaa tgttgggttc tagctccctg ttctccaaac ccatactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaagtc ccaccacctg cacatgtgta
 781 gccccaccag ccctccaagg cattgctcgc ccaagcagct ggtaattcca ttcatgtgat
 841 tagatgtccc ctggccctct gtcccctctt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
1021 agagcccaga aagtggctgc agacaaaatc aataaaacta atgtccctcc cctctccctg
1081 ccaaaaggca gttacatata aatacagaga ctcaaaggtca ctagaatagg gccagctggg
1141 tcaatgtgaa gcccacaaatt tgcccagatt cacttttctt ccccccactcc cttttttttt
1201 tttttttttt tgagatggag ttctgctctt gtcacccacg ctggagtgca atggtgtggg
1261 cttggcttat tgaagcctct gcctcctggg ttcaaagtat tctcttgct cagcctcctg
1321 agtagctggg attacaggtt cctgttacca cgcccagcta atttttgtat ttttagtaga
1381 gacgaggtt caccatgttg gccaggctgg tctcgaaact ctgtcctcag gtaatccgcc
1441 caccctagcc tcccacaaagt ctgggattac aggcgtgagc cacagtgcct ggcctcttcc
1501 ctctccccc accttttttt ttttttttat ggcaggggtc cactctgtcg
1561 cccaggtctg agtgacgtgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta caggtgtgtg ccactacggc
1681 tggctaaatt ttgtattttt agtagagaca ggtttcacca tattggccag gctggtcttg
1741 aactcctgac ctcaaagtat ccaccttctt tgtgctccca aagtgtctgag attacaggcg
1801 tgagctatca caccagcctt cccctttttt ttcctaatag gagactcctg tacctttctt
1861 cgttttacct atgtgtcgtg tctgtttaca tttctttctc cctcaggctt tttttgggt
1921 ggtcttccaa cctccaatac ccaggcctgg cctcttcaga gtacccccc tccactttc
1981 cctgcctcct tctttaataa gctgacaatc aaattcatgc tatggtgtga aagactacct
2041 ctgacttggt attataagct ggagttatat atgtatttga aaacagagta aatacttaag
2101 aggccaaata gatgaatgga agaattttag gaactgtgag agggggacaa ggtgaagctt
2161 tcttgccctt gggaggaagc tggctgtggt agcgtagcgc tctctctctc tgtctgtggc
2221 agggagccaa gagtaggggt taattgagtg aaggaaacct gggtagagac cattctcagg
2281 tgggtggggt agggctaaaga ctgggagttg ggtctatcta tgcccttctg gctgattttt
2341 gtagagacgg gggtttgcca tgttaccag gctggtctca aactcctggg ctcaagcgat
2401 cctcttggtc cagcctccca aagtgtctgg attacaggcg tgaatcactg cgcttggtt
2461 cctcttctct ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgttaca agtgtctggt cctttctgag ggaggctggt gccgctctgc
2581 aggggtattt aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
2641 aatcacagtg agaattgttca ccttataggc ttgctgtggg gctcagggtt aaagtgtggg
2701 gagtgacact gcctaggcat ccagctcagt gtcattccagg gcctgtgtcc ctcccgaacc
2761 caggggtcaac ctgcctgcca caggcactag aaggacgaat ctgcctactg cccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctgtc ctgtccttgc ccctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

//
LOCUS      HSU83239      932 bp      mRNA      PRI      02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION  U83239
NID        g2062424
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Molecular cloning and functional characterization of a novel CC
            chemokine STCP-1 which specifically acts on activated T
lymphocytes
JOURNAL     Unpublished
REFERENCE  2 (bases 1 to 932)
AUTHORS    Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D.,
            Meng,T., Boone,T. and Andrew,D.P.
TITLE      Direct Submission
JOURNAL     Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620
            University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES   Location/Qualifiers
            source          1..932
                        /organism="Homo sapiens"
                        /note="Amgen EST program"
                        /db_xref="taxon:9606"
            CDS             15..296
                        /codon_start=1
                        /product="CC chemokine STCP-1"
                        /db_xref="PID:g2062425"

/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```



```

                                LPLRVVKKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQ"
BASE COUNT      166 a      330 c      201 g      235 t
ORIGIN
    1 atacaggaca gagcatggct cgcttacaga ctgcactcct ggttgctctc gtcctccttg
   61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
  121 gctgccgtga ttacgtccgt taccgtctgc ccttgccgct ggtgaaacac ttctactgga
  181 cctcagactc ctgcccaggg cctggcgtgg tgttgctaac cttcagggat aaggagatct
  241 gtgccgatcc cagagtggcc tgggtgaaga tgattctcaa taagctgagc caatgaagag
  301 cctactctga tgaccgtggc cttggctcct ccaggaaggc tcaggagccc tacctccctg
  361 ccattatagc tgctccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
  421 ccctgtggct gtcacccttg gtcacctcgg tgctgtcact gccatctccc cctgacccc
  481 tctaacccat cctctgcctc cctccctgca gtcagagggt cctgttcccc tcagcgatcc
  541 ccttgcttaa acccttccat gactccccac tgccctaagc tgaggtcagt ctcccaagcc
  601 tggcatgtgg ccctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
  661 atgaatgttg ggttctagct ccctgttctc caaacccata ctacacatcc cacttctggg
  721 tctttgcctg ggaagtgtct gacactcaga aagtcaccac acctgcacat gtgtagcccc
  781 accagccctc caaggcattg ctgcaccaag cagctggtaa ttccatttca tgtattagat
  841 gtccctggc cctctgtccc ctcttaataa ccctagtcac agtctccgca gattcttggg
  901 atttgggggt tttctcccc accctccac ta

//
LOCUS      HSMCP1          725 bp      RNA          PRI          03-APR-1995
DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
ACCESSION  X14768
NID        g34513
KEYWORDS   monocyte chemoattractant protein 1.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 725)
AUTHORS    Yoshimura,T., Yuhki,N., Moore,S.K., Appella,E., Lerman,M.I. and
            Leonard,E.J.
TITLE      Human monocyte chemoattractant protein-1 (MCP-1). Full-length
CDNA
            cloning, expression in mitogen-stimulated blood mononuclear
            leukocytes, and sequence similarity to mouse competence gene JE
JOURNAL    FEBS Lett. 244 (2), 487-493 (1989)
MEDLINE    89153605
COMMENT    ZAPII.
FEATURES   Location/Qualifiers
            source          1..725
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="glioma cells"
                        /cell_line="U105MG"
                        /clone_lib="lambda"
            sig_peptide     54..122
                        /note="signal peptide (AA -23 to -1)"
            CDS             54..353
                        /codon_start=1
                        /product="monocyte chemoattractant preprotein"
                        /db_xref="PID:g34514"
                        /db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLLIATFIQGLAQPDAINAPVTCCYNFTNRKIS
VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT"
            mat_peptide     123..350
                        /note="MCP-1 (AA 1 - 76)"
            misc_feature     162..170
                        /note="pot. N-linked glycosylation site"
            misc_feature     707..712
                        /note="pot. polyA signal"
            polyA_site       725
                        /note="polyA site"
BASE COUNT      208 a      171 c      126 g      220 t
ORIGIN
    1 ctaaccacaga aacatccaat tctcaaaactg aagctcgcac tctcgccctcc agcatgaaag
   61 tctctgccgc ccttctgtgc ctgctgctca tagcagccac cttcattccc caagggctcg
  121 ctcagccaga tgcaatcaat gcccagtcga cctgctgtta taacttcacc aataggaaga
  181 tctcagtgcga gaggctcgcg agctatagaa gaatcaccag cagcaagtgt cccaagaaga

```

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt attttcccct agctttcccc agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaatgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgtttttta
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt ttttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
721 tgtac

//
LOCUS      HSMCP2          2991 bp      DNA              PRI          20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        g1905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
AUTHORS    Van Coillie,E., Fiten,P., Nomiya,H., Sakaki,Y., Miura,R.,
            Yoshie,O., Van Damme,J. and Opdenakker,G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
JOURNAL     Genomics 40 (2), 323-331 (1997)
MEDLINE     97237052
REFERENCE   2 (bases 1 to 2991)
AUTHORS     Opdenakker,G.M.M.
TITLE       Direct Submission
JOURNAL     Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven,
            BELGIUM
FEATURES    Location/Qualifiers
            source          1..2991
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
                        /map="q11.2"
            repeat_region   209..219
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region   240..248
                        /note="DR-B"
                        /rpt_type=DIRECT
            CAAT_signal      296..300
            repeat_region   310..318
                        /note="IR-A"
                        /rpt_type=INVERTED
            repeat_region   406..415
                        /note="DR-B"
                        /rpt_type=DIRECT
            repeat_region   407..416
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region   425..435
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region   429..437
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region   455..465
                        /note="IR-C"
                        /rpt_type=INVERTED
            TATA_signal      467..472
            repeat_region   492..502
                        /note="IR-C"
                        /rpt_type=INVERTED
            repeat_region   492..500
                        /note="IR-A"

```

```

        /rpt_type=INVERTED
    exon      534..639
               /gene="MCP-2 (SCYA10)"
               /number=1
    gene      534..1969
               /gene="MCP-2 (SCYA10)"
    CDS       join(534..639,1331..1448,1864..1969)
               /gene="MCP-2 (SCYA10)"
               /codon_start=1
               /product="monocyte chemotactic protein-2"
               /db_xref="PID:e279930"
               /db_xref="PID:g1905801"

    /translation="MLKLTPLPSKMKVSAALLCLLLMAATFSPQGLAQPDVSIPITC
    CFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTQRGKEVCADPKERWVRDSMKHLDDQ
    IFQNLKP"
    intron    640..1330
               /gene="MCP-2 (SCYA10)"
               /number=1
    exon      1331..1448
               /gene="MCP-2 (SCYA10)"
               /number=2
    intron    1449..1863
               /gene="MCP-2 (SCYA10)"
               /number=2
    exon      1864..1969
               /gene="MCP-2 (SCYA10)"
               /number=3
BASE COUNT   799 a    709 c    632 g    851 t
ORIGIN
1 agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61 tggggttcta aaggagcttg cctggccttag aactgcaagt gactctagtg tgatggagag
121 caccagcaaa gccttagggc ccatccctgg cctcctgtta cccacagagg ggtaagcctt
181 ggctctcttc cactatgacg tcagcttcca ttcttctctt cttatagaca attttccatt
241 tcaaggaaat cagagccctt aatagttcag tgaggctact ttgctgagca caatcccata
301 cccttcagcc tctgtccac agagcctaag caaagatag aaactcaca cttccttggt
361 ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggtctt
421 acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481 agagccaccg aggagcagag aggttgagaa caaccagaa accttcacct ctcatgctga
541 agctcacacc cttgccctcc aagatgaagg ttcttcgagc gcttctgtgc ctgtgctca
601 tggcagccac tttcagccct cagggacttg ctcagccagg taagacctct ccttttttaa
661 ggggagacca aaagaggaat taagaagagc cattatgtca cagctcataa ggaacaaaac
721 cagaactaaa ggctcaggtc actgaggctg gtcccttga tcttctctga cccagtttt
781 gggaggagac agtgagccg ctacagcaac aacctccca ttgtttgggg aaataatcca
841 gaacgaagaa ctgttttcta ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
901 agaaactatt gcctgaagct tcaaattttg gtatgggttc agtgacctt ccagaacagt
961 ggctgtgtaa agaggatgag gaccagagg aatctcagcg tatggcatag gctaactcta
1021 aagcccatga ggatgaaaga ctgggaagca aggtattgga acttatgttc ccagtgctag
1081 aagttttggg ttagtagaca aggactagct tgttactcaa aatgtttcca aaccagttca
1141 acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
1201 gggatctgga ctaagacact gaacttgga tggtagcttc ttggtcttct ctttcttctt
1261 cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321 tttctttcag attcagtttc cattccaatc acctgctgct ttaacgtgat caataggaaa
1381 attcctatcc agaggctgga gagtacaca agaattacca acatccaatg tcccaaggaa
1441 gctgtgatgt gagtggacag tgccctggc cccattcaa aagttctgat ggacaacata
1501 gagaagtcaa gattcatgtc catatgagtc ggatgcatat aacttctatc caaagggggc
1561 ctctacccca tagagaaact cagtccgtga gaaggagtcc ataactgtc taggatcccc
1621 ttctaggggc ttggtgaaac taaccacaata tctgtagcca ggaccttga gggtttcacc
1681 tggacagcaa gagcagagct tccttctgga gcttcttctt cccactcttc ccttcccttc
1741 tctccgggt cgggtctctt cacttaagga ccaagggtcg atcagtccta gggaccaatg
1801 gccacagtc ctgtgcagga tcttcaaagt cttccatcta attgtgccct ccttcccca
1861 cagcttcaag acccaacggg gcaaggaggt ctgtgctgac cccaaggaga gatgggtcag
1921 ggattccatg aagcatctgg accaaatatt tcaaaatctg aagccatgag cttcataca
1981 tggactgaga gtcagagctt gaagaaaagc ttattttatt tccccaaact cccccagggt
2041 cagtgtgaca ttattttatt ataactcca caaagagatt atttttaaat aatttaaagc
2101 ataattttc ttaaaaagta ttaattata ttaagtgtg tgatgtttta actctatctg
2161 tcatacatcc tagtgaatgt aaaaagcaaa atcctggtga tgtgtttttt gtttttgggt
2221 tctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctctt acctgtctgt
2281 agtgttgtgg ggtcctccca tggatcatca aggtgaaaca ctttggtatt ctttggcaat
2341 cagtgtctct gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tggaattttg aaaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gaggtagttt tgggcatcat
2521 gggtagacagt ttgggcatgg acggggccatt tttcaagaat gtcttctggc tacgctggac
2581 tcaaccaagg ttctcagaga acttggtggg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccttgattcg ctagcctctc ttgtttctct tgtttatata
2701 ttatccagcc taaggatttt tggtatagct gccccaaaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tggaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgacccg ccatattgag ccatacatc cgagcttatt atttttccag
2941 cttattggga aaacacgtct aaggcaaaac aatttattgt actgttgaac c
//LOCUS      HSY16645      1368 bp      mRNA      PRI      25-SEP-1998
DEFINITION   Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION    Y16645
NID           g2916795
KEYWORDS      MCP-2 gene; monocyte chemotactic protein 2.
SOURCE        human.
  ORGANISM     Homo sapiens
                Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
                Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1368)
  AUTHORS      Van Coillie,E.
  TITLE        Functional comparison of two human monocyte chemotactic
protein-2      isoforms, role of the amino-terminal pyroglutamic acid and
                processing by CD26/dipeptidyl peptidase IV
  JOURNAL      Biochemistry 37, 12672-12680 (1998)
REFERENCE    2 (bases 1 to 1368)
  AUTHORS      Van Coillie,E.
  TITLE        Direct Submission
  JOURNAL      Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical        Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT       Related sequences: X99886, Y10802.
FEATURES      Location/Qualifiers
  source       1..1368
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /chromosome="17"
                /tissue_type="testis"
                /clone_lib="Clontech"
                /clone="HL1142q"
                /map="ql1.2"
  gene         473..772
                /gene="MCP-2"
  sig_peptide  473..541
                /gene="MCP-2"
  CDS          473..772
                /gene="MCP-2"
                /codon_start=1
                /product="monocyte chemotactic protein-2"
                /db_xref="PID:e1253690"
                /db_xref="PID:g2916796"

/translation="MKVSAALLCLLLMAATFSPQGLAQPDVSVIPITCCFNVINRKIP
IQRLESYTRITNIQCPKEAIVFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
  mat_peptide  542..769
                /gene="MCP-2"
  variation    677
                /gene="MCP-2"
                /note="polymorphism, Lys -> Gln"
                /replace="c"
BASE COUNT    457 a      292 c      243 g      376 t
ORIGIN
  1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
  61 tcctgttacc cacagagggg taggcccttg gctctcttc actatgacgt cagcttccat
  121 tcttcctttc ttatagacaa ttttccattt caaggaaatc agagccctta atagttcagt
  181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gaggcctaagc
  241 aaaagataga aactcacaac ttccttgttt tgttatctgg aaattatccc aggatctggt
  301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgccc
  361 aggcctctcg ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaac

```

```

421 aacccagaaa ctttcacctc tcatgctgaa gctcacaccc ttgccctcca agatgaagggt
481 ttctgcagcg cttctgtgcc tgctgctcat ggcagccact ttccagccctc aggggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaat
601 tcctatccag aggcctggaga gctacacaag aatcaccaac atccaatgtc ccaagggaagc
661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gaccccaagg agagatgggt
721 cagggattcc atgaagcatc tggaccacaa atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcagag cttgaagaaa agcttattta ttttcccca cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtatttaatt atatttaagt tgttgatgtt ttaactctat
961 ctgtcatata tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgttttg
1021 ttttctgtg agctcaacta agttcacggc aaaatgtcat tgttctccct cctacctgtc
1081 tgtagtgtg tggggctctc ccattgatca tcaaggtgaa acactttggt attctttggc
1141 aatcagtgtc cctgtaagtc aaatgtgtgc tttgtactgc tgttgttgaa attgatgta
1201 ctgtatataa ctatggaatt ttgaaaaaaa atttcaaaaa gaaaaaaata tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
//LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION   H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION    X72308 S57464
NID          g313707
KEYWORDS     monocyte chemotactic protein 3.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE        Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of           the cDNA and comparison with other chemokines
JOURNAL      Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE      93213290
REFERENCE    2 (bases 1 to 1085)
AUTHORS      Opdenakker,G.M.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University   of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE    3 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
              Speleman,F., Laureys,G. and Van Damme,J.
TITLE        The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
              assignment to the C-C chemokine gene cluster on chromosome
              17q11.2-q12
JOURNAL      Genomics 21 (2), 403-408 (1994)
MEDLINE      94375065
FEATURES
  source      Location/Qualifiers
              1..1085
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
  gene        299..810
              /gene="MCP-3"
  CDS         299..628
              /gene="MCP-3"
              /codon_start=1
              /product="monocyte chemotactic protein-3"
              /db_xref="PID:g313708"
              /db_xref="SWISS-PROT:P80098"

/translation="MWKMPSPSPNMKASAALLCLLLTAAAFSPQGLAQFVGINTSTTC
CYRFINKKIPKQRLSEYRRTTSSHCPRFAVIFKTKLDKEICADPTQKWVQDFMKHLDK
      sig_peptide      299..397
                        /gene="MCP-3"
      mat_peptide      398..625
                        /gene="MCP-3"
                        /product="monocyte chemotactic protein-3"
      polyA_signal      806..810
                        /gene="MCP-3"
BASE COUNT      314 a      214 c      229 g      328 t

```

ORIGIN

```

1  ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggttaat cactgctggt
121 tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccc ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cttttctcag agtgggtctg agattatatt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781 gatttttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841 ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggttat tgtataagtc cttgcaagaa tcagtgcata gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

//

```

LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of         the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source          1..1085
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            gene            299..810
                        /gene="MCP-3"
            CDS              299..628
                        /gene="MCP-3"
                        /codon_start=1
                        /product="monocyte chemotactic protein-3"
                        /db_xref="PID:g313708"
                        /db_xref="SWISS-PROT:P80098"

/translation="MWKPMSPSPNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWQDFMKHLDK
            sig_peptide    299..397
                        /gene="MCP-3"
            mat_peptide    398..625

```

```

/ gene="MCP-3"
/ product="monocyte chemotactic protein-3"
polyA_signal 806..810
/ gene="MCP-3"
BASE COUNT      314 a      214 c      229 g      328 t
ORIGIN
1  gggtttctatt gacttggggtt aatcgtgtga ccgcgggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctggt
121 tcccgtggggg gtgtgggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaaggc aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccagggt gcttgcctcag ccagtgggga ttaatacttc
421 aactacctgc tgcacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccc ggaagctgta atcttcaaga ccaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaac aaataatttg tataccctgt cctttctcag agtggttctg agattatttt
721 aatctaattc taaggaaatg gagctttatg taataatgtg aatcatggtt tttcttagta
781 gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt ggttttgaac
841 ataaagcctt ggatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctccct
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcгаа gatttgcttt
961 aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaat ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

//LOCUS      HSU46767      825 bp      mRNA      PRI      16-DEC-1996
DEFINITION    Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
complete cds.
ACCESSION     U46767
NID           gl732122
KEYWORDS
SOURCE        human.
ORGANISM      Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1 (bases 1 to 825)
AUTHORS       Garcia-Zepeda,E.A., Combadiere,C.C., Rothenberg,M.E.,
Sarafi,M.N., Lavigne,F., Hamid,Q., Murphy,P. and Luster,A.D.
TITLE         Human monocyte chemoattractant Protein (MCP)-4: A novel CC
chemokine with activities on monocytes, eosinophils, and
basophils
induced in allergic and non-allergic inflammation that signals
through the CC chemokine receptors CCR-2 and 3
JOURNAL       J. Immunol. 158 (1996) In press
REFERENCE     2 (bases 1 to 825)
AUTHORS       Garcia-Zepeda,E.A. and Luster,A.D.
TITLE         Direct Submission
JOURNAL       Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
Disease Unit, Massachusetts General Hospital, 149 13th St.,
Charlestown, MA 02129, USA
FEATURES
source        Location/Qualifiers
1..825
/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="heart"
/clone_lib="EG3.16"
sig_peptide   34..102
/ gene="MCP-4"
CDS           34..330
/ gene="MCP-4"
/ note="small cytokine; intercrine/chemokine; C-C
subfamily     signature; chemoattractant for monocytes, eosinophils"
/codon_start=1
/product="monocyte chemoattractant protein-4
precursor"
/db_xref="PID:gl732123"

/translation="MKVSAVLLCLLLMTAAFNPQGLAQPDALNVPSTCCFTFSSKKIS

```

LQRLKSYVITTSRCPQKAVIFRTKLGEICADPKEKWVQNYMKHLGRKAHTLKT"

gene 34..330
/gene="MCP-4"
mat_peptide 103..327
/gene="MCP-4"

BASE COUNT 221 a 175 c 185 g 244 t

ORIGIN

```

1 acattgtgaa atctccaact cttaaccttc aacatgaaag tctctgcagt gcttctgtgc
61 ctgctgctca tgacagcagc tttcaacccc cagggacttg ctcagccaga tgcactcaac
121 gtcccatcta cttgctgctt cacatttagc agtaagaaga tctccttgca gaggctgaag
181 agctatgtga tcaccaccag cagggtgtccc cagaaggctg tcatcttcag aaccaaactg
241 ggcaaggaga tctgtgctga cccaaaggag aagtgggtcc agaattatat gaaacacctg
301 ggccggaaag ctcacaccct gaagacttga actctgctac ccctactgaa atcaagctgg
361 agtacgtgaa atgacttttc cattctcctc tggcctcctc tcttatgctt tggaatactt
421 ctaccataat ttcaaataag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
481 agtaatatgt gctattattt gacttggtgc tggtttgag tttatttgag tattgctgat
541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagcccc ttccttcca
601 ctatgagctg ctggcagtg gttgtattcg gttcccaggg gttgagagca tgcctgtggg
661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
781 tgcagaaaat acattttatt taaatctcc taaaaaaaa aaaaa

```

//LOCUS HSAMAC1 803 bp RNA PRI 10-AUG-1997
DEFINITION Homo sapiens mRNA for alternative activated macrophage specific
CC

chemokine 1.
ACCESSION Y13710
NID g2326515
KEYWORDS AMAC-1 gene; CC-chemokine 1.
SOURCE human. ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

Homo.

REFERENCE 1 (bases 1 to 803)

AUTHORS Politz,O.

TITLE Direct Submission

JOURNAL Submitted (10-JUN-1997) Politz O., Dermatology, Free University
Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200

Berlin

GERMANY

REFERENCE 2 (bases 1 to 803)

AUTHORS Kodolja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
Goerdts,S.

TITLE Cloning of alternative activated macrophage associated CC

chemokine

1 (AMAC-1)

JOURNAL Unpublished

FEATURES

Location/Qualifiers

source

1..803

/organism="Homo sapiens"

/db_xref="taxon:9606"

/cell_type="macrophage"

sig_peptide

71..133

/gene="amac-1"

CDS

71..340

/gene="amac-1"

/note="macrophage specific"

/codon_start=1

/product="CC-chemokine 1"

/db_xref="PID:e321838"

/db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKELCCLVYTSWQIPQKFI

VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

gene

71..340

/gene="amac-1"

mat_peptide

134..337

/gene="amac-1"

BASE COUNT 214 a 213 c 160 g 216 t

ORIGIN


```

1 cccggcagcag agggagtgtg agtttccaag cccagctca ctctgaccac ttctctgcct
61 gcccagcatc atgaagggcc ttgcagctgc cctccttgtc ctctgtctgca ccatggccct
121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgcctcgtct atacctcctg
181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccagc gcccgaagcc
241 aggtgtcatc ctccaaacca agagagggcg gcagatctgt gctgacccca ataagaagtg
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gcccagtgaa cttggtgggc ccaggagggg acaggagcct gagccagggc aatggccctg
421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
481 ctttaatctt agtttatgca tcatatttca tttgaaatt gatttctatt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttccctt
601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
661 cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggtttt gctcagacc
721 accttttaat atattggcag tacttattat ataaaaggta aaccagcatt ctcactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

//
LOCUS      HUMLD78A      3176 bp      DNA              PRI      17-JAN-1992
DEFINITION Human LD78 alpha gene.
ACCESSION  D90144
NID        g219905
KEYWORDS   LD78; LD78 alpha; cytokine; inducible gene family; secreted
           peptide.
SOURCE     Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 3176)
AUTHORS    Nakao,M., Nomiya,H. and Shimada,K.
TITLE      Structures of human genes coding for cytokine LD78 and their
           expression
JOURNAL    Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE    90287155
COMMENT     These data kindly submitted in computer readable form by:
Hisayuki   Nomiya
           Department of Biochemistry
           Kumamoto University Medical School
           2-2-1 Honjo, Kumamoto 860
           Japan
           Phone: 096-344-2111
           Fax: 096-372-6140.
FEATURES   Location/Qualifiers
           source          1..3176
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
           TATA_signal     1041..1045
           exon            1069..1227
                           /number=1
           prim_transcript 1069..2957
                           /note="LD78 alpha mRNA and introns"
           sig_peptide     1155..1220
                           /note="LD78 alpha signal peptide"
           CDS              join(1155..1227,1916..2030,2451..2541)
                           /codon_start=1
                           /product="LD78 alpha precursor"
                           /db_xref="PID:d1014875"
                           /db_xref="PID:g219906"

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQ
NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA"
           mat_peptide     join(1218..1227,1916..2030,2451..2538)
                           /partial
                           /note="LD78 alpha mature peptide"
           intron          1228..1915
           exon            1916..2030
                           /partial
                           /number=2
           intron          2031..2450
           exon            2451..2957
                           /number=3

```

```

BASE COUNT      833 a    741 c    752 g    850 t
ORIGIN
1  acccagggac  ctatcacaca  aatataagaa  ctattcattc  ttttaaggcat  gtattttccaa
61  gcctttgtat  ttttttccat  gcttaggggt  ggcaagggaat  atatatatat  ttgtacaaat
121  atatatgtgt  atatgtacaa  atacatgtat  atatatagta  aatatatata  tatatttgta
181  caattcttca  gactttgtag  aattttgata  atgtcgtatc  ttgctttttt  taaccactga
241  tgttataagc  atattttatgc  cacttcattc  attttagaga  cttaataata  aatgatctag
301  tggataattt  atcattccct  gatggagaaa  aatttagcct  tgtttatttt  agagttataa
361  acgatgctgg  gtcagggtatc  tttatgtttg  aagatggctc  catatttggg  ttgtttccac
421  agaactcttt  cctagaaatg  ctttttctag  gttaatggct  acagatattt  ctaggcacct
481  gacatattga  caccacacct  taaagtattt  ttatgatcca  caactagcgt  ttaaccagc
541  gccctagtca  ctacatgact  aataaataga  caaatgactg  aaacatgacc  tcatgtcttc
601  tattcctcca  gctttcattc  agttctttgc  ctctgggagg  aggaagggtt  gtgcagccct
661  ccacagcatc  agcccatcaa  ccctatccct  gtggttatag  cagctgagga  agcagaattg
721  cagctctgtg  ggaaggaatg  gggctggaga  gttcatgcac  agaccagttc  ttatgagaag
781  ggactgacta  agaatagcct  tgggttgaca  tatacccctc  ttcacactca  caggagaaac
841  catttcccta  tgaactata  acaagtcagt  agttgagagc  tgagagttag  agaatagtct
901  aaagatgcta  ttcttgata  tcctgagccc  ctgtgttcac  cagggaccct  gagttgtgca
961  acttagcatg  acagcatcac  tacgcttaaa  aatttccctc  ctcaccccca  gattccattt
1021  ccccatccgc  cagggttgc  tataaaggag  agagctgggt  tcagacttca  gaaggacag
1081  ggcagcagac  agtggtcagt  cctttcttgg  ctctgctgac  actcgagccc  acattccgtc
1141  acctgtcag  aatcatgcag  gtctccactg  ctgcccctgc  tgcctccttc  tgcaccatgg
1201  ctctctgcaa  ccagttctct  gcatacagtg  agtctgagtt  tcgttgtggg  tatcaccact
1261  ctctggccat  ggttagacca  catcaatctt  ttcttgtggc  ctaaaagccc  ccaagagaaa
1321  agagaacttc  ttaaagggct  gccaaacatc  ttggtctttc  tctttaagac  ttttattttt
1381  atctctagaa  ggggtcttag  ccccctagtc  tccaggtatg  agaacttagg  caggggcagg
1441  ggagttacag  tcccttttac  agatagaaaa  acagggttcg  aaacgaatca  gtttagcaaga
1501  ggagaaatcc  agggctgctt  acttcccagt  ggggtatgtt  gttcactctc  cagctcactc
1561  taggtctccc  aggagctctg  tcccttggat  gtcttatgag  agatgtccaa  ggcttctctt
1621  ggggtggggt  atgacttctt  gaaccagaca  aaattccctg  aagagaactg  agataagaga
1681  acagtccgtt  caggatcttg  gatcacacag  agaaacagag  aaccactat  gaagagtcaa
1741  ggagaaagaa  ggatacagac  agaaacaaag  agacatttct  cagcaaaaat  gccccaatgc
1801  ctccagtcga  cttggtctga  gcaagcctgc  ctctctcaac  tgctcgggga  tcagaagctg
1861  cctggccttt  tctcttgagc  tgtgactcgg  gctcattctc  ttcttctctc  cacagtgtct
1921  gctgacacgc  cgaccgctg  ctgcttcagc  tacacctccc  ggcagattcc  acagaatttc
1981  atagctgact  actttgagac  gagcagccag  tgctccaagc  ccggtgtcat  gtaagtccca
2041  gtcttcctgc  tcacctctat  ggaggtaggg  agggtcaggg  ttggggcaga  gacaggccag
2101  aaggctatcc  tggaaaggcc  cagccttcag  gagcctatcg  gggatacagg  acgcagggct
2161  ccgaggtgtg  acctgacttg  gagctggagt  gaggcagtgt  ttacagagtc  aggaagggct
2221  gccccagccc  agaggaaagg  gacaggaaga  aggaggcagc  gggacactct  gaggggccac
2281  cctactgagt  cactgagaga  agctctctag  acagagatag  gcagggggcc  cctgaaagag
2341  gagcaagccc  tgagctgccc  aggacagaga  gcagaatggt  gggggccatg  tggggccagg
2401  attcccctgc  tggattcccc  agtgcttaac  tcttctcccc  ttctccacag  ctctctaacc
2461  aagcgaagcc  ggcaggctct  tgctgacccc  agtgaggagt  ggggtccagaa  atatgtcagc
2521  gacctggagc  tgagtgcctg  aggggtccag  aagcttcgag  gccagcgac  ctcggtgggc
2581  ccagtgggga  ggagcaggag  cctgagcctt  gggaacatgc  gtgtgacctc  cacagctacc
2641  tcttctatgg  actggttgtt  gccaaacagc  cacactgtgg  gactcttctt  aacttaaat
2701  ttaatttatt  tatactattt  agtttttgta  atttattttc  gatttcacag  tgtgtttgtg
2761  attgtttgct  ctgagagttc  cctgttcccc  tcccccttcc  ctacacccgc  gtctgtgac
2821  aaccgagtg  ctgtcatcag  cctgtgtagg  cagtcatggc  accaaagcca  ccagactgac
2881  aaatgtgtat  cggatgcttt  tgttcagggc  tgtgatcggc  ctggggaaat  aataaagatg
2941  ctcttttaaa  aggtaaacca  gtattgagtt  tggttttgtt  tttctggcaa  atcaaaatca
3001  ctggttaaga  ggaatcatag  gcaaagatta  ggaagagggt  aaatggaggg  aaattgggag
3061  agatggggag  ggctaccaca  gagttatcca  ctttacaacg  gagacacagt  tctggaacat
3121  tgaactacg  aatatgttat  aactcaaata  ataacatgca  tgctctagga  gaattc
//
LOCUS      AF043339      225 bp      mRNA      PRI      23-FEB-1998
DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
mRNA,
partial cds.
ACCESSION  AF043339
NID        g2905627
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 225)
AUTHORS    Jang, J.S. and Kim, B.E.
TITLE      Direct Submission
JOURNAL    Submitted (15-JAN-1998) Protein Engineering, General Institute

```

of Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong, Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
reverse primer (5'-cttctggaccctcaggcact-3').

FEATURES
Location/Qualifiers
source 1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"
gene <1..225
/gene="MIP1a"
primer_bind <1..19
/gene="MIP1a"
/PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30 cycles;
DeltaCycler II from Ericomp"
CDS <1..213
/gene="MIP1a"
/function="CC chemokine"
/function="proinflammatory cytokine involved in inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSYTSRQIPQNFADYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"
primer_bind complement(205..225)
/gene="MIP1a"

BASE COUNT 50 a 68 c 62 g 45 t
ORIGIN
1 gcacacattg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccgggtgct
121 atcttcctaa ccaagcgaag ccggcaggtc tgtgctgacc ccagtgagga gtgggtccag
181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag

//
LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992
DEFINITION Human LD78 beta gene.
ACCESSION D90145
NID g219907
KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted peptide.
SOURCE Human placenta DNA, clone Lm LD-1.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.
REFERENCE 1 (bases 1 to 3112)
AUTHORS Nakao,M., Nomiya,H. and Shimada,K.
TITLE Structures of human genes coding for cytokine LD78 and their expression
JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE 90287155
COMMENT These data kindly submitted in computer readable form by:
Hisayuki Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES
Location/Qualifiers
source 1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"
repeat_unit 498..797
/note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS              join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
              QNFIADYPETSSQCSKPSVIFLTRGRQVCADPSEEWQKYVSDLELSA"
sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide      join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron           1268..1952
exon             1953..2067
                  /number=2
intron           2068..2487
exon             2488..2955
                  /number=3

BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
1  ttagagactt aataataaag gatcttgttg ataatttata attccctgat agagaaaaat
61 ttagctttgc ttatttttaga gttataaatg atgctggggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctagggt
181 aatggctaca catatttcta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa ctagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tccttccctc
361 tgggaggact gggggttgct tagccctcca cagcatcagc ccattgacct tatccttggt
421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagaggt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcac tttgttgcc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc cccacctcc tgggttcaag
601 cgattctcct gccctcagcc tcccagtag ctgggattac aggcattgtc caccacgctt
661 gactactttt gtatttttag tagagatgga gtttctcttt ctgggtcagg ttggtctcaa
721 actcctgacc tcagggtgat cgcagcctcg gcctcccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacaccctt cttcacactc acaggagaaa ccccatgaag ctagaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatatcctg
961 agccctgtg gtaccagggt accctgagtt gtgcaacact cagcatgaca gcatcactac
1021 acttaaaaat ttccctcttc accccagatg tccatttccc catccgccag ggtgcctat
1081 aaagaggaga gatggcttca gacatcagaa ggacgcaggc agcaaagagt agtcagtcct
1141 ttcttggtct tgctgacact cgagcccaca ttccatcacc tgctcccaat catgcagggt
1201 tccactgctg cccttgccgt cctcctctgc accatgggtc tctgcaacca ggtcctctct
1261 gcaccacgtg agtccatggt gttgttgttg gtatcaccac tctctggcca tgggttagacc
1321 acatcagttt ttttttgctg cctgagagcc ccgaagagaa aagaagggaag ttcttaaagc
1381 gctgcccac accttggtct ttttcttcac aacttttatt tttatctcta gaagggtctt
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtcctct
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggtt
1561 gcttacttcc cagtgggttc tgtgtttcac tctccagctc accctagggt tcccaggagc
1621 cctgtccctt ggtgtcttta tgagagatgt ccagggtctc tcttgggtct ggggtatgact
1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaac agtccattca ggtatctgga
1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaaagagga atatagacag
1801 aaacaaagag acatttctct gcaaaacccc ccaaatgcct tgcagtcact tggcttgagc
1861 aagcctgccc tcttcaacca ctcagggtat agaagctgct tggccttttc ttctgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgctgct gacacgccga ccgctgctg
1981 cttcagctac acctcccgac agattccaca gaatttcata gctgactact ttgagacgag
2041 cagccagttc tccaagcccc gtgtcatgta agtgccagtc ttcctgctca cctctaggga
2101 ggtaggaggt ctcagggttg gggcagaaac aggcagaaag gccatcctgg aaaggccag
2161 ccttcaggag cctatcgggg atacaggagc cagggcactg aggtgtgacc tgacttgggg
2221 ctggagttag gtgggtgtta cagagtcagg aagggctgcc ccaggccaga ggaaaggaac
2281 aggaagaagg aggcagcagg acactcttag ggcctcttgg cctggagtca ctgagagaa
2341 ctctctagac ggagataggc agggggcccc tgagagagga gcaggccttg agctgccag
2401 gacagagagc aggatgtcag gccatggttg gcccaggatt ccccggttgg attccccagt
2461 gcttaactct tcttcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```

```

2521 tgacccagcaggagggtggg tccagaaata cgtcagtgac ctggagctga gtgcctgagg
2581 ggtccagaag cttcgaggcc cagcgacctc agtggggccca gtggggagga gcaggagcct
2641 gagccttggg aacatgcgtg tgacctctac agctacctct tctatggact gggtattgac
2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttatttat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gttttgtgatt gtttgctctg agagttcccc
2821 ctgtccccc caccctccct cacagtgtgt ctggtgacga ccgagtggct gtcacgggcc
2881 tgtgtaggca gtcattggcac caaagccacc agactgacaa atgtgtatca gatgcttttg
2941 ttcagggctg tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaaccagt
3001 attgagtttg gttttgtttt tctggcaaat caaatcact agttaagagg aatcataggc
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

//
LOCUS      HUMACT2A      696 bp      mRNA      PRI      30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION  J04130
NID        g178017
KEYWORDS   act2 gene; immune activation gene.
SOURCE     Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 696)
AUTHORS    Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE      Identification, cloning, and characterization of an immune
            activation gene
JOURNAL     Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE     89071764
COMMENT     Draft entry and computer-readable sequence [1] kindly submitted
            by
            W.Leonard, 09-JAN-1989.
FEATURES   Location/Qualifiers
            source          1..696
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /map="Unassigned"
            mRNA            <1..696
                        /note="act-2 mRNA"
            sig_peptide     109..177
                        /gene="LAG2"
                        /note="act-2 protein signal peptide"
            gene            109..387
                        /gene="LAG2"
            CDS             109..387
                        /gene="LAG2"
                        /note="act-2 protein precursor"
                        /codon_start=1
                        /db_xref="GDB:G00-127-452"
                        /db_xref="PID:g178018"

/translation="MKLCVTVLSLLMLVAAFCSPALSPMGSDDPPTACCFSYTARKLP
            RNFVVDYYETSSLCSQPAVVFQTKRSKQVCADPSESQVQYVVDLELN"
            mat_peptide     178..384
                        /gene="LAG2"
                        /note="act-2 protein"
BASE COUNT 157 a 203 c 139 g 197 t
ORIGIN      Unreported.
            1 ttcccccccc ccccccccc ccccgcccca gcacaggaca cagctgggtt ctgaagcttc
            61 tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
            121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
            181 ccaatgggct cagaccctcc caccgcctgc tgcctttctt acaccgcgag gaagcttctc
            241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
            301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
            361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt cagggaaggt
            421 cacctgagcc cggatgcttc tccatgagac acatctcttc catactcagg actcctctcc
            481 gcagtttctg tcccttctct taatttaac tttttatagt gccgtgttat tgtattaggt
            541 gtcatcttca tttttatat tagtttagcc aaaggataag tgcctatgg ggaatggcca
            601 ctgtcactgt ttctctgctg ttgcaaatat atggataaca catttgattc tgtgtgtttt
            661 ccataataaa acttttaaat aaaatgcaga cagtta

//
LOCUS      AF031587      481 bp      mRNA      PRI      02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901
 California Ave, Palo Alto, CA 94304, USA
 FEATURES
 source Location/Qualifiers
 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"
 /translation="MKVSVAAALSCLMLVAVLGSAQFINDAETELMMSKLPLENFVVV
 NSFHFAADCTSYISQIPCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLPYSI"
 BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN
 1 atgaaggtct cctgtgctgc cctctcctgc ctcattgctt ttgctgtcct tggatcccag
 61 gccaggttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaaat
 121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacia
 181 agcatcccggt gtctactcat gaaaagtatt ttgaaaacga gcagcgagtg ctccaagcca
 241 ggtgtcatat tcctcaccaa gaaggaggag caagtctgtg ccaaaccag tgggtccggga
 301 gtccaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
 361 gggcagccac ccacctccaa cactcctgtg gagtttcttg gtctgaaata cttaaaaaat
 421 atatatattg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttcaattttt
 481 t
 //
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,
 partial cds.
 ACCESSION AF043340
 NID g2905629
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 234)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of
 Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgacccctggccactgaactg-3')
 reverse primer (5'-ccttccttctgtcagttgga-3').
 FEATURES
 source Location/Qualifiers
 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"

```

gene <1..234
      /gene="MIP2a"
primer_bind <1..21
              /gene="MIP2a"
              /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
CDS DeltaCycler II from Ericomp"
      <1..222
      /gene="MIP2a"
      /function="CXC chemokine"
      /function="proinflammatory cytokine involved in
inflammation"
      /note="8-10 kDa"
      /codon_start=1
      /product="macrophage inflammatory protein 2 alpha"
      /db_xref="PID:g2905630"

/translation="APLATELRCQCLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATL
KNGQKACLNPASPMVKKIIEKMLKNGKSN"
primer_bind complement(214..234)
      /gene="MIP2a"
BASE COUNT 74 a 70 c 54 g 36 t
ORIGIN
1 gcacccctgg ccactgaact gcgctgccag tgcttgaga ccctgcaggg aattcacctc
61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgcca aaccgaagtc
121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catggttaag
181 aaaatcatcg aaaagatgct gaaaaatggc aaatccaact gaccagaagg aagg

//
LOCUS HSU77035 764 bp mRNA PRI 23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
complete cds.
ACCESSION U77035
NID g1790924
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 764)
AUTHORS Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
Zlotnik,A.
TITLE Identification through bioinformatics of two new macrophage
proinflammatory human chemokines: MIP-3alpha and MIP-3beta
J. Immunol. 158 (3), 1033-1036 (1997)
JOURNAL MEDLINE 97166046
REFERENCE 2 (bases 1 to 764)
AUTHORS Rossi,D.L. and Zlotnik,A.
TITLE Direct Submission
JOURNAL Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
California Ave., Palo Alto, CA 94304, USA
FEATURES
source Location/Qualifiers
1..764
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="elutriated monocytes activated with
LPS/IFN-GAMMA"
gene 1..291
/gene="MIP-3a"
CDS 1..291
/gene="MIP-3a"
/note="chemokine"
/codon_start=1
/product="macrophage inflammatory protein 3 alpha"
/db_xref="PID:g1790925"

/translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRILHPK
FIVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTVWKYIVRLLSKVKVM"
BASE COUNT 235 a 121 c 146 g 260 t 2 others
ORIGIN
1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgcgtct actccacctc

```

```

61  tgcggcgaat  cagaagcagc  aagcaacttt  gactgctgtc  ttggatacac  agaccgtatt
121 cttcctccta  aatttattgt  gggcttcaca  cggcagctgg  ccaatgaagg  ctgtgacatc
181 aatgctatca  tctttcacac  aaagaaaaag  ttgtctgtgt  gcgcaaattc  aaaacagact
241 tgggtgaaat  atattgtgcg  tctcctcagt  aaaaaagtca  agaaccatgt  aaaactgtgg
301 cttttctgga  atggaattgg  acatagccca  agaacagaaa  gaaccttgct  ggggttggag
361 gtttcacttg  cacatcatgg  agggtttagt  gcttatctaa  tttgtgcctc  actggacttg
421 tccaattaat  gaagttgatt  catattgcat  catagtttgc  tttgtttaag  catcacatta
481 aagttaaaact  gtattttatg  ttatttatag  ctgtagggtt  tctgtgttta  gctatttaac
541 actaattttc  cataagctat  tttggtttag  tgcaaagtat  aaaattatat  ttggggggga
601 ataagattat  atggactttt  ttgcaagcaa  caagctattt  tttaaaamma  actatttaac
661 attcctttgt  ttatattggt  ttgtctccta  aattgttgta  attgcattat  aaaataagaa
721 aaatattaat  aagacaaata  ttgaaaataa  agaacaacaa  agtt

```

```

//
LOCUS      HSU77180      545 bp      mRNA      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
complete cds.
ACCESSION  U77180
NID        g1791002
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL    J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE    97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="macrophages activated with LPS or IFNg"
                        /chromosome="9"
            gene            1..297
                        /gene="MIP-3beta"
            CDS              1..297
                        /gene="MIP-3beta"
                        /function="chemokine"
                        /codon_start=1
                        /product="macrophage inflammatory protein 3 beta"
                        /db_xref="PID:g1791003"

```

/translation="MALLLALLSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR"

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPDQFWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 125 a 160 c 153 g 107 t

```

ORIGIN
1  atggccctgc  tactggccct  cagcctgctg  gttctctgga  cttccccagc  cccaactctg
61  agtggcacca  atgatgctga  agactgctgc  ctgtctgtga  cccagaaacc  catccctggg
121  tacatcgtga  ggaacttcca  ctaccttctc  atcaaggatg  gctgcagggt  gcctgctgta
181  gtgttcacca  cactgagggg  cgcgcagctc  tgtgcacccc  cagaccagcc  ctgggtagaa
241  cgcacatccc  agagactgca  gaggacctca  gccaaagtga  agcgccgcag  cagttaacct
301  atgaccgtgc  agaggagacc  cggagtccga  gtcaagcatt  gtgaattatt  acctaacctg
361  gggaaccgag  gaccagaagg  aaggaccagg  cttccagctc  ctctgcacca  gacctgacca
421  gccaggacag  ggctgggggt  gtgtgtgagt  gtgagtgtga  gcgagagggg  gagtgtgggtc
481  tagagtaaag  ctgctccacc  cccagattgc  aatgctacca  ataaagccgc  ctggtgttta
541  caact

```

```

//
LOCUS      HUMTCSM      1160 bp      mRNA      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```


KEYWORDS Alu repeat; T-cell-specific protein.
 SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA,
 clone 228.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1160)
 AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J.,
 Clayberger,C., Davis,M.M. and Krensky,A.M.
 TITLE A human T cell-specific molecule is a member of a new gene family
 JOURNAL J. Immunol. 141, 1018-1025 (1988)
 MEDLINE 88285659
 COMMENT Draft entry and computer-readable sequence for [1] kindly provided
 by A.M.Krensky, 24-OCT-1988.
 FEATURES
 source Location/Qualifiers
 1..1160
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 27..302
 /note="T cell-specific protein precursor"
 /codon_start=1
 /db_xref="PID:g339421"
 /translation="MKVSAARLAVILIATLALCAPASAPYSSDTPCCFAYIARPLPR
 AHIKEYFYTSKGKSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS"
 sig_peptide 27..95
 /note="T cell-specific protein signal peptide"
 mat_peptide 96..299
 /note="T cell-specific protein"
 repeat_region 450..950
 /note="Alu-related repeats"
 BASE COUNT 298 a 332 c 295 g 235 t
 ORIGIN 276 bp upstream of RsaI site.
 1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
 61 tcattgctac tgcctctctgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
 121 cctgctgctt tgcctacatt gcccgccac tgcctcgtgc ccacatcaag gagtatttct
 181 acaccagtgg caagtgtccc aacccagcag tcgtctttgt caccgcaaag aaccgccaag
 241 tgtgtgccaa cccagagaag aaatgggttc gggagtagat caactctttg gagatgagct
 301 aggatggaga gtccttgaa ctagaacttac acaaatttgc ctgtttctgc ttgctcttgc
 361 cctagcttgg gaggcttccc ctactatccc taccaccacc gctccttgaa gggccagat
 421 tctgaccacg acgagcagca gttacaaaaa ccttccccag gctggacgtg gtggctcagc
 481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
 541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagccgg
 601 gcgtggttagc gggcgctgt agtcccagct actcgggagg ctgaggcagg agaattggcgt
 661 gaacccggga gcggagcttg cagtgcgccc agatcgccc actgcactcc agcctgggcg
 721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaatata aaaattagcc
 781 gcgtgggtgc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
 841 gaacccagga ggtggaggct gcagtgcgct gagattgtgc cacttcactc cagcctgggt
 901 gacaaagtga gactccgtca caacaacaac aacaaaaagc ttccccaaact aaagcctaga
 961 agagcttctg aggcgctgct ttgtcaaaag gaagtctcta ggttctgagc tctggcttgc
 1021 ccttggcttt gcaagggctc tgtgacaagg aagggaagtca gcatgcctct agagggaagg
 1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
 1141 gcaaacatga aaatcgggg
 //
 LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995
 DEFINITION Human secreted protein (I-309) mRNA, complete cds.
 ACCESSION M57502
 NID g339728
 KEYWORDS secreted protein.
 SOURCE Human T-cell, cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 520)
 AUTHORS Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.
 TITLE A novel polypeptide secreted by activated human T lymphocytes
 JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522

FEATURES

source Location/Qualifiers

1..520

/organism="Homo sapiens"

/db_xref="taxon:9606"

/cell_type="T-cell"

/germline

/map="17"

mRNA <1..520

/gene="SCYA1"

/note="G00-118-872"

gene 1..520

/gene="SCYA1"

CDS 51..341

/gene="SCYA1"

/codon_start=1

/db_xref="GDB:G00-118-872"

/product="secreted protein I-309"

/db_xref="PID:g339729"

/translation="MQIITTAIVCLLLAGMWPEDVDSKSMQVPPSRCCFSFAEQEIPL
RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK"

BASE COUNT 140 a 137 c 122 g 121 t

ORIGIN

1 accaggctca tcaaagctgc tccaggaagg cccaagccag accagaagac atgcagatca

61 tcaccacagc cctgggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca

121 agagcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagattcccc

181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat

241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggaacac agttggatgg gtccagaggc

301 acagaaaaat gctgaggcac tgcccgtcaa aaagaaaatg agcagatttc ttccattgt

361 gggctctgga aaccacatgg cttcacctgt cccgaaact accagcccta caccattcct

421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttggtg

481 cactttaaac atttaaatta tacaatcatc aacccccaac

//

LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997

DEFINITION Human mRNA for EB11-ligand chemokine, complete cds.

ACCESSION AB000887

NID g2189952

KEYWORDS EB11-ligand chemokine; ELC.

SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

Homo.

REFERENCE 1 (bases 1 to 687)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,

Kitaura,M.,

Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.

TITLE Direct Submission

JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.

Hisayuki Nomiya, Kumamoto University Medical School,

Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan

(E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

REFERENCE 2 (sites)

AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,

Kitaura,M.,

Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.

TITLE Molecular cloning of a novel human CC chemokine EB11-ligand

chemokine that is a specific functional ligand for EB11, CCR7

JOURNAL J. Biol. Chem. 272 (21), 13803-13809 (1997)

MEDLINE 97298088

FEATURES

source Location/Qualifiers

1..687

/organism="Homo sapiens"

/db_xref="taxon:9606"

/dev_stage="fetal"

/tissue_lib="lung"

gene 139..435

/gene="ELC"

```

CDS             139..435
                /gene="ELC"
                /note="CC chemokine"
                /codon_start=1
                /product="EBI1-ligand chemokine"
                /db_xref="PID:d1021215"
                /db_xref="PID:g2189953"

/translation="MALLLALLSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGRVPAVVFTTLRGRQLCAPDPQWVERIIQRLQRTSAKMKRRSS"
mat_peptide     202..432
                /gene="ELC"
                /product="EBI1-ligand chemokine"
polyA_signal    657..662
BASE COUNT     154 a    223 c    173 g    137 t
ORIGIN
1 cattcccagc ctcacatcac tcacaccttg cattcaccc ctgcatecca gtcgccctgc
61 agcctcacac agatcctgca cacaccaga cagctggcgc tcacacattc accgttggcc
121 tgcctctgtt caccctccat ggccttgcta ctggccctca gcctgctggt tctctggact
181 tccccagccc caactctgag tggcaccaat gatctgaag actgctgcct gtctgtgacc
241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggtggc
301 tgcaggggtg ctgctgtagt gttcaccaca ctgaggggccc gccagctctg tgcaccccca
361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
421 cgccgcagca gttaacctat gaccgtgcag agggagcccg gaggccaggt caagcattgt
481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
541 ctgcaccaga cctgaccagc caggacaggg cctgggggtg gtgtgagtg gtgtgtgagc
601 gagagggtga gtgtggtcag agtaaagctg ctccaccccc agattgcaat gctaccaata
661 aagccgcctg gtgtttacaa ctaattg

//
LOCUS           AB000221       760 bp    mRNA             PRI       31-JUL-1997
DEFINITION      Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION       AB000221
NID             g2289718
KEYWORDS        CC chemokine; PARC; pulmonary and activation-regulated
chemokine.
SOURCE          Homo sapiens lung cDNA to mRNA.
ORGANISM        Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;      Homo.
REFERENCE       1 (bases 1 to 760)
AUTHORS         Nomiyama,H.
TITLE           Direct Submission
JOURNAL         Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
                Hisayuki Nomiyama, Kumamoto University Medical School,
Department      of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
                (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
                Fax:81-96-372-6140)
REFERENCE       2 (sites)
AUTHORS         Hieshima,K., Imai,T., Baba,M., Shoudai,K., Ishizuka,K.,
                Nakagawa,T., Tsuruta,J., Takeya,M., Sakaki,Y., Takatsuki,K.,
                Miura,R., Opdenakker,G., Damme,J., Yoshie,O. and Nomiyama,H.
TITLE           A novel human CC chemokine PARC that is most homologous to
macrophage-inflammatory protein-1alpha/LD78alpha and
chemotactic     for T lymphocytes, but not for monocytes
JOURNAL         J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE         97376836
FEATURES        Location/Qualifiers
                source          1..760
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
                                /tissue_type="lung"
                gene            64..333
                                /gene="PARC"
                CDS              64..333
                                /gene="PARC"
                                /note="pulmonary and activation-regulated chemokine"

```

```

/codon_start=1
/product="CC chemokine"
/db_xref="PID:d1022520"
/db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCCLVYTSWQIPQKFI
VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
BASE COUNT      186 a      208 c      155 g      211 t
ORIGIN
    1 gccaggagtt gtgagtttcc aagcccccage tcactctgac cacttctctg cctgcccage
   61 atcatgaagg gccttgacgc tgcctcctt gtccctgtct gcaccatggc cctctgtctc
  121 tgtgcacaag ttgttaccaa caaagagctc tgcctcctcg tctatacctc ctggcagatt
  181 ccacaaaagt tcatagttga ctattctgaa accagcccc agtgccccaa gccagggtgc
  241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
  301 aaatacatca ggcacctgaa gctgaatgcc tgaggggcct ggaagctgag agggcccagt
  361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccaccct
  421 ggaggccacc tcttctaaga gtcccatctg ctatgcccag ccacattaac taactttaat
  481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
  541 aattagtatt ttctctgaca ttctatgaca ttgtctttat catcctttcc cctttccctt
  601 caactcttcg tacattcaat gcatggatca atcagtgtga ttagctttct cagcagacat
  661 tgtgccatat gtatcaaag acaaatcttt attgaatggt ttgctcagc accacctttt
  721 aatatattgg cagtacttat tatataaaag gtaaaccagc

//
LOCUS      D86955      799 bp      mRNA      PRI      06-MAR-1997
DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
ACCESSION  D86955
NID        gl871138
KEYWORDS   CC chemokine LARC precursor.
SOURCE      Homo sapiens cDNA to mRNA.
  ORGANISM  Homo sapiens
    Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
    Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
    Hominidae;
      Homo.
REFERENCE  1 (sites)
  AUTHORS  Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
    Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
    Nomiya,H.
  TITLE    Molecular cloning of a novel human CC chemokine liver and
    activation-regulated chemokine (LARC) expressed in liver.
    Chemotactic activity for lymphocytes and gene localization on
    chromosome 2
  JOURNAL  J. Biol. Chem. 272 (9), 5846-5853 (1997)
  MEDLINE  97190319
REFERENCE  2 (bases 1 to 799)
  AUTHORS  Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
    Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
    Nomiya,H.
  JOURNAL  Unpublished (1996)
REFERENCE  3 (bases 1 to 799)
  AUTHORS  Nomiya,H.
  TITLE    Direct Submission
  JOURNAL  Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
    Hisayuki Nomiya, Kumamoto University Medical School,
    Department
    of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
    (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
FEATURES
  source      Location/Qualifiers
              1..799
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /chromosome="2"
              /map="q33-37"
  sig_peptide 59..136
              /gene="LARC"
  CDS         59..349
              /gene="LARC"
              /codon_start=1
              /product="CC chemokine LARC precursor"
              /db_xref="PID:d1013880"
              /db_xref="PID:gl871139"

```

```

/translation="MCCTKSLLLAALMSVLLHLHLCGESEASNFDCCLGYTDRIILHPK
              FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM"
gene          59..349
              /gene="LARC"
mat_peptide   137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT    240 a    138 c    153 g    268 t
ORIGIN
1 cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat
61 gtgctgtacc aagagtttgc tcctggctgc tttgatgtca gtgctgctac tccacctctg
121 cggcgaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct
181 tcactcctaaa tttattgtgg gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
241 tgctatcatc tttcacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
361 tttctggaat ggaattggac atagcccaa gacagaaaaga accttgctgg gggtggaggt
421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgtc
481 caattaatga agttgattca tattgcata tagtttgctt tgtttaagca tcacattaaa
541 gttaaactgt attttatggt atttatagct gtaggttttc tgtgtttagc tatttaatac
601 taattttcca taagctattt tggtttagtg caaagtataa aattatattt gggggggaat
661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
721 cttttgttta tattgttttt tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
781 cattaataag acaaatatt

//
LOCUS          HUMAR          538 bp    mRNA          PRI          11-SEP-1996
DEFINITION     Human mRNA for chemokine, complete cds.
ACCESSION      D43767
NID            g1536878
KEYWORDS       chemokine, thymus and activation-regulated; chemokine.
SOURCE         Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
               Homo.
REFERENCE      1 (sites)
AUTHORS        Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
               Yoshie,O.
TITLE          Molecular cloning of a novel T cell-directed CC chemokine
expressed      in thymus by signal sequence trap using Epstein-Barr virus
vector
JOURNAL        J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE        96355526
REFERENCE      2 (bases 1 to 538)
AUTHORS        Imai,T.
JOURNAL        Unpublished (1996)
REFERENCE      3 (bases 1 to 538)
AUTHORS        Imai,T.
TITLE          Direct Submission
JOURNAL        Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
               Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
               Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source       1..538
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="D3A"
               /sex="male"
               /tissue_type="peripheral blood"
  CDS          53..337
               /note="thymus and activation regulated"
               /codon_start=1
               /product="chemokine"
               /db_xref="PID:d1008410"
               /db_xref="PID:g1536879"

/translation="MAPLKMLALVTLGLGASLQHIHAARGTNVGRECCLEYFKGAIP
              RKLKWTYQTSSEDCSRDAIVFVTQGRAICSDPNKRKVNKNAVYKLSLERS"

```

BASE COUNT 118 a 168 c 149 g 103 t
ORIGIN

```

1 ccctgagcag agggacctgc acacagagac tccctccttg gctcctggca ccatggcccc
61 actgaagatg ctggcccttg tcaccctcct cctgggggct tctctgcagc acatccacgc
121 agctcgaggg accaatgtgg gccgggagtg ctgctggag tacttcaagg gagccattcc
181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
241 ttttctaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctctcaccc cagactcctg
361 actgtctccc gggactacct gggacctcca ccgttggtgt tcaccgcccc caccctgagc
421 gcctgggtcc aggggaggcc ttccagggac gaagaagagc cacagtggag gagatcccat
481 ccccttgctc gaactggagc catgggcaca aagggccag attaaagtct ttatcctc

```

//

LOCUS HUMEOTAXIN 807 bp mRNA PRI 25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION D49372
NID gi1552240
KEYWORDS eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

Homo.

REFERENCE 1 (bases 1 to 807)

AUTHORS Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
Tiffany,H.L., Murphy,P.M. and Yoshie,O.

TITLE Molecular cloning of human eotaxin, an eosinophil-selective CC
chemokine, and identification of a specific eosinophil eotaxin
receptor, CC chemokine receptor 3

JOURNAL J. Biol. Chem. 271 (13), 7725-7730 (1996)

MEDLINE 96205964

REFERENCE 2 (bases 1 to 807)

AUTHORS Yoshie,O.

TITLE Direct Submission

JOURNAL Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.

Osamu

Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)

COMMENT On Sep 20, 1996 this sequence version replaced gi:1313900.

FEATURES Location/Qualifiers

source

1..807

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="141"

/tissue_type="Small intestine, proximal"

CDS

99..392

/codon_start=1

/product="eotaxin"

/db_xref="PID:d1008966"

/db_xref="PID:gi1552241"

/translation="MKVSAALLWLLLIAAFSPQGLAGPASVPTTCCFNLNRKIPLQ

misc_signal 548..557

/note="mRNA destabilization signal"

polyA_signal 775..780

polyA_site 807

BASE COUNT 229 a 198 c 147 g 233 t

ORIGIN

```

1 gcattttttc aagttttatg atttatttaa cttgtggaac aaaaataaac cagaaaccac
61 caccctctcac gccaaagctc acaccttcag cctccaacat gaaggtctcc gcagcatttc
121 tgttggtgct gctcatagca gctgccttca gccccaggg gctcgtctgg ccagcttctg
181 tcccaaccac ctgctgcttt aacctggcca ataggaagat acccttcag cgactagaga
241 gctacaggag aatcaccagt ggcaaatgtc ccagaaaagc tgtgatcttc aagaccaaac
301 tggccaagga tatctgtgcc gaccccaaga agaagtgggt gcaggattcc atgaagtatc
361 tggaccacaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
421 agcctgagtg ttgcctaatt tgttttcctt tcttacaatg cattctgagg taacctcatt
481 atcagtccaa agggcatggg ttttattata tataatatata tttttttttt aaaaaaac
541 gtattgcatt taatttattg aggccttaaa acttatcctc catgaatatc agttattttt

```

```

601 aaactgtaaa gctttgtgca gattctttac cccctgggag cccaattcg atccccctgc
661 acgtgtgggc aatgttcccc ctctcctctc ttcctccctg gaatcttgta aaggctcctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttgtgaac ccaaagtgtg actcattaaa
781 tggaagtaaa tgttgtttta ggaatac

//
LOCUS      HSCCHEMA      232 bp      RNA      PRI      10-SEP-1996
DEFINITION H.sapiens mRNA for CC-chemokine.
ACCESSION  Z69291
NID        g1181148
KEYWORDS   CC-chemokine.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 232)
  AUTHORS  Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
  TITLE    Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
  JOURNAL  Unpublished
REFERENCE  2 (bases 1 to 232)
  AUTHORS  Bartels,J.H.
  TITLE    Direct Submission
  JOURNAL  Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet zu Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE  3 (bases 1 to 232)
  AUTHORS  Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroder,J.M.
  TITLE    Human dermal fibroblasts express eotaxin: molecular cloning,
            mRNA
            expression, and identification of eotaxin sequence variants
  JOURNAL  Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
  MEDLINE  96374440
FEATURES   Location/Qualifiers
    source  1..232
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /clone="clones 4(9512),
            14(9512),15(9512),10(9601),11(9601)"
            /tissue_type="foreskin"
            /cell_type="fibroblast"
            /sex="Male"
    mRNA    <1..>232
            /citation=[1]
            /product="CC-chemokine"
    sig_peptide 56..109
            /citation=[1]
    CDS       56..>232
            /function="putative chemoattractant protein"
            /note="sequence homology to human MCP-1, MCP-2 and
MCP-3       and to rodent eotaxins"
            /citation=[1]
            /codon_start=1
            /product="CC-chemokine, preprotein"
            /db_xref="PID:e221070"
            /db_xref="PID:g1181149"
            /db_xref="SWISS-PROT:P50877"

/translation="MKVSAALLWLLIIAAAFSPQGLAGPASVPTTCCFNLANRKIPLQ
            RLESYRRITSGKCPQ"
    mat_peptide 110..>232
            /citation=[1]
            /function="putative chemoattractant protein"
            /product="CC-chemokine"
BASE COUNT  55 a      82 c      50 g      42 t      3 others
ORIGIN
      1 accaaaccag aaaccwccam ytctcacgcc aaagtcaca cttcagcct ccaacatgaa

```

```

61 ggtctccgca gcgcttctgt ggctgctgct catagcggct gccttcagcc cccaggggct
121 cgctgggcca gcttctgtcc caaccactg ctgctttaac ctggccaata ggaagatacc
181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag

//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS    Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
            Knappe,P.
            and Forssmann,W.G.
TITLE      Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS    Pardigol,A.
TITLE      Direct Submission
JOURNAL    Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower      Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
            Hannover, Lower Saxon, 30625, Germany
FEATURES   Location/Qualifiers
            source          1..4037
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /clone="ph3b7"
                        /dev_stage="adult"
                        /tissue_type="placenta"
                        /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                        /sex="male"
            TATA_signal     727..733
                        /note="putative, determined by consensus rules."
            5'UTR           764..833
                        /note="first base determined by means of consensus
rules"
            exon            764..912
                        /note="first base determined by means of consensus
rules;
                        base 780 is the first base of cDNA (Z49270)"
            CDS              1..3672
                        /number=1
                        join(834..912,3021..3135,3585..3672)
                        /codon_start=1
                        /product="chemokine HCC-1"
                        /db_xref="PID:g1004267"

/translation="MKISVAAIPFFLLITIALGKTESSSRGPYPHSECCFTYTTYKI
            PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPDKWVQDYIKDMKEN"
            intron          913..3020
                        /number=1
            exon            3021..3135
                        /number=2
            intron          3136..3584
                        /number=2
            exon            3585..3817
                        /number=3
            3'UTR           3673..3817
BASE COUNT  1023 a   1048 c   1004 g   962 t
ORIGIN
1 gagctccggtt gggagtcacca tgtttcttta tggcataatg ggtgagaaca cagacttgga
61 agccaaacca cctgaatttg aaccccagtt ccatttacca actgtcaaaa gcttaggctt
121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
181 ggcaactggg acagtggcct gtgtgtatag caaccattat ataagtgaat tatctactga
241 gcaccacagc acttcttcac tccatgggtg ggtgaccaga atggagatga gacagagAAC
301 tgcaggttct gcttcgagtt taagttagga ttcccttga ccaatgagac ctgacttgga
361 ggagtcctgg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
421 gaatgtccag gccccacgtg gcctgttcta aggcctgaga tgggaattgga tacaggacac

```



```

481 atccagcctt gagatctttt gctaagtgtg acacagtgcc cccagccctg tgctcatgtt
541 catgcctagg gaaaggcttc tatcaaaaga gttgaacttc tccccactgg ggaatggaaga
601 ccatttcttc ccttaaacct tggctctccc tgcttcttc aggccaccaa caacacatgt
661 gcaggatatg aaattgctga ggcatcactg ctttctact tcccttccaa gtctcagctc
721 ccttatttta aaaaatattt ggctcaatg atcatttctc aacaattcct caccgcagga
781 gcctctgaag ctcccaccag gccagctctc ctcccacaac agcttccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctcc tcatcccat cgccctaggg accaagactg
901 aatcctcttc acgtgagtgc aatgccttgt cttccttcca acctagagcc tgcagggaaa
961 taagcaggag tgaggttggg gctcagggga agaccaggag cagggactca gaaaggaggg
1021 ctggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtgtgga gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagttaaag ttgggatctt ccagccttga ccaatgagac ttgacttggg
1201 agactccagg cttcattcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct cttatcattg cccccagga ccagtcctcc
1321 cttgccctca aggacatgga gtgagaccag cctgcctctc tactcctcta atttctctt
1381 ctttgccgct aagcaaaaga gtggccacc ccatttgggg tatatttctt cagggagatt
1441 aggagcagtg ctttgagccc ctcaagggca tttttctatt ggcttctga ggttggggc
1501 cagcctgctt ccagcgtcac ctgtgccag tgagtgcagc attgttggg tatggctgg
1561 ggggaaacac gacagtgtgg ggtccatcct agggccctt ttctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta tttatcactc ttccatttta cctactcttc
1681 ttttcagaaa ctggggggaa accgaagggt gttaaaatac agctaaagt ggtaggtatg
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagagggaac aaggtgggag
1801 agtataggag ctctgactgg gctcaggaa acagggggcc cttatgcccgt tctttggatc
1861 gtgaggatgc tgccctggaat tgagctggaa aacaggatga gaccttcca cccagacatc
1921 tggccaccct cagtgcctc tgaggccatt gtgatgcaca tccatgattc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgctctgtt
2041 gtacagggct cttggcctac aatgtccttc ctgctacctc tataattcaa gttgggggtg
2101 gctgctgtca ccttgttctt cctataaaag ccatgaaact tctcaatcag aaaaatagatg
2161 aaaaaatcac ccaatccagt gattttttaa actttttaga ccacaaaacc ttttctcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtagggtaca
2281 agacaccact ctcaaatgca gcaaggcctc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaagggc ctcatctaca gaggagggaa cagggggaaa
2401 gtataatggc cacagtacac aggaagcaca ggcaagggtta ggttaggatt tgggtgccc
2461 gactctgtgg cctttgtcct tggggcttgc tgtgggcatc ctgctctctc tgcaggttgt
2521 cggttcaatg gggacatggg cagggtggag cactaggagg ggctgggttt gcattcccaa
2581 atggcatgtc tccaaatccc tatgggatt tcttccaaat attcctcta tttggagcac
2641 ctttcccga taaggcatga aggtctgatg atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctcttcaa tccctggagt
2761 gaaagtcac caccagtctt tccaagaggg gttgaagaaa agggaggagg gtgattgatg
2821 atgagggagg agaaaaagaa gagcccagga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctcccctcc aagtctctgag gggctgtctc ctcttctct cctctctcca
2941 tggcctcagc ttgcaggagc agccaatggt atggccttta acaaggggccc cctcctcagc
3001 atctgatgct ctctctcag ggggacctta ccacccctca gagtgtgct tcacctacac
3061 tacttacaag atcccgctc agcgatttat ggattactat gagaccaaca gccagtgtc
3121 caagcccgga attgtgtagg ttgtacacac acatcacact ggggggagag ggagccagca
3181 gggcctctg gagggaaagca gggagtgtg gtggaatggg gacccccagc gtacctccca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgcttctt ggctggagcc
3301 tgcaggagcc atggggaaac tgaccccatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagaggg cacttctca gggggacaca gagactagat gggcttaggg gtcttaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgtgga agaaaggaaa
3481 agcagtatag gtcaggtggg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actgggcccc tcggtttgtg atccttctcc ctcttctctc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa cccagtgac aagtgggtcc aggactatat caaggacatg
3661 aaggagaact gactgaccca gaagggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaagg cccctctctc caccaccgc taactctcag cccagtcac cctctggag
3781 cttccctgct ttgaattaaa gaccactcat gctcttccct ggcctcatc ctttctacg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcacctcgg catcaagcct
3901 cgctctgcag aagttttggt ggagcctggt acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctcct cctcagcagg
4021 aacagtagca gaccccc

```

//

```

LOCUS      HSCC21      925 bp      mRNA      PRI      30-JUN-1998
DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION  Z70292
NID        g1296608
KEYWORDS   chemokine CC-1; chemokine CC-2.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 925)

```

AUTHORS Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
 Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.
 TITLE HCC-2, a human chemokine: gene structure, expression pattern,
 and biological activity
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
 MEDLINE 98263352
 REFERENCE 2 (bases 1 to 925)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..925
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233855"
 /db_xref="PID:g1296609"
 /db_xref="SWISS-PROT:Q16663"

 /translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSPFHAADCCTSYISQSIPLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..780
 /codon_start=1
 /evidence=experimental
 /product="chemokine CC-1"
 /db_xref="PID:e233856"
 /db_xref="PID:g1296610"
 /db_xref="SWISS-PROT:Q16627"

 /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
 PRQRIMDYETNSQCSKPGIVFITKRHGSVCTNPSPDKWVQDYIKDMKEN"
 3'UTR 781..925
 polyA_signal 902..908
 BASE COUNT 240 a 296 c 199 g 190 t
 ORIGIN
 1 ccaggaagca gtgagcccg gagtccctcg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttgat cccaggccca
 121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgctcca agccagggtgt
 301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtgggtc cgggagtcca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
 481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
 541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
 601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
 661 accaacagcc agtgctccaa gcccgaatt gtcttcatca ccaaaagggg ccattccgtc
 721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
 781 gtgacccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
 841 ccctcctcca cccaccgcta actctcagcc ccagtcaccc tcttgagct tccctgcttt
 901 gaattaaaga ccactcatgc tcttc
 //

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol, A., Maegert, H.J., Zucht, H.D., Forssmann, W.G. and
 Schulz-Knappe, P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol, A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31. Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAAALSCMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSHFHAADCCTSYISQSI PCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFLLITIALGKTTESSQTGGKPKVVKIQLKLVG
 PYHPSECCFTYTTYKIPRQIRIMDYETNSQCSKPGIVFITKRGHVSVCTNP SDKWVQDY
 IKDKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgectcat gcttggtgct gtccttgat cccaggccca
 121 gttcacaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaagcat
 241 cccgtgttca ctcataaaaa gttattttga aacgagcagc gagggtcca agccaggtgt
 301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagtcca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccaccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctctctcc

```

AUTHORS   Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
          Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.
TITLE     HCC-2, a human chemokine: gene structure, expression pattern.
and
          biological activity
JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
MEDLINE   98263352
REFERENCE 2 (bases 1 to 925)
AUTHORS   Pardigol,A.
TITLE     Direct Submission
JOURNAL   Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
Biology,  Lower Saxony Institute for Peptide Research, Feodor-Lynen-
Strasse    31, Hannover, Lower Saxony, 30625, Germany
FEATURES   Location/Qualifiers
            source          1..925
                              /organism="Homo sapiens"
                              /db_xref="taxon:9606"
                              /dev_stage="adult"
                              /tissue_type="liver"
                              /clone_lib="PCR fragments"
            5'UTR          1..55
            CDS             56..397
                              /note="putative; first coding region of a bicistronic
                              mRNA"
                              /codon_start=1
                              /product="chemokine CC-2"
                              /db_xref="PID:e233855"
                              /db_xref="PID:g1296609"
                              /db_xref="SWISS-PROT:Q16663"

/translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
NSFHFAADCTSYISQSIPLKMSYFETSSECSKPGVIFLTKGRQVCAKPSGPGVQ
            misc_feature    DCMKKLKPYSI"
            398..498
            /note="spacing region between two coding regions of
the
            bicistronic mRNA"
            CDS             499..780
                              /codon_start=1
                              /evidence=experimental
                              /product="chemokine CC-1"
                              /db_xref="PID:e233856"
                              /db_xref="PID:g1296610"
                              /db_xref="SWISS-PROT:Q16627"

/translation="MKISVAAIPFFLLITIALGKTESSSRGYPHPSECCFTYTTYKI
            PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSPDKWVQDIKDMKEN"
            781..925
            polyA_signal    902..908
BASE COUNT  240 a    296 c    199 g    190 t
ORIGIN
      1 ccaggaagca gtagcccgag gtagctctcg ccagccctgc ctgcccacca ggaggatgaa
     61 ggtctccgtg gctgcccctc cctgcctcat gcttggtgct gtccctggat cccaggccca
    121 gttcacaaat gatgcagaga cagagttaat gatgtcaaag cttccactgg aaaatccagt
    181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
    241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgtctca agccagggtg
    301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagttca
    361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
    421 gccaccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
    481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
    541 accatcgccc tagggaccaa gactgaatcc tcctcacggg gaccttacca ccctcagag
    601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
    661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaagggg ccattccgtc
    721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
    781 gtgaccaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
    841 ccctcctcca cccaccgcta actctcagcc ccagtcaccc tcttgagact tccctgcttt
    901 gaattaaaga ccactcatgc tcttc
//

```

```

1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

```

//

```

LOCUS      AB007454      1503 bp      mRNA      PRI      09-APR-1998
DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
ACCESSION  AB007454
NID        g2723285
KEYWORDS   chemokine LEC precursor.
SOURCE      Homo sapiens liver cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS     Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
            Yoshie,O. and Nomiyama,H.
TITLE       Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
JOURNAL      Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
MEDLINE      98207719
REFERENCE  2 (bases 1 to 1503)
AUTHORS      Nomiyama,H.
TITLE        Direct Submission
JOURNAL       Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiyama, Kumamoto University Medical School,
            Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
            Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
FEATURES             Location/Qualifiers
     source            1..1503
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
                       /tissue_type="liver"
     sig_peptide        77..145
     CDS                77..439
                       /codon_start=1
                       /product="chemokine LEC precursor"
                       /db_xref="PID:d1024963"
                       /db_xref="PID:g2723286"

/translation="MKVSEALSLVLILITSASRSQPKVPEWVNTPTCCLKYYEK
VLPRLVVG YRKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYKDPNLP LLLPTRNLS
TVKIITAKNGQPQLNSQ"
     mat_peptide        146..436
     polyA_signal       560..565
     polyA_signal       1485..1490
BASE COUNT      417 a      374 c      312 g      400 t
ORIGIN
1  gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61  ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tcctcatcct
121 tatcattact tcggcttctc gcagccagcc aaaagttcct gagtgggtga acaccccatc
181 cacctgtctg ctgaagtatt atgagaaagt gttgccaaag agactagtgg tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
421 gctcctcaac tcccagtgat gaccaggctt tagtggaaag cctgttttac agaagagagg
481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtatttcga atattttctc aactcttagga
601 ggaaatacca aagttaaggg acgtgggcag aggtacgctc tttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgcg gtgggtgtgat
721 cttggctcac ttgatcttgg ctactgttaa cctccacctc ccaggctcaa gtgatcctcc
781 caccacgccc tcccagtag ctgggactac aggtctgcgc caccacacct ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tgttgccag gctgggtctc aactctgttg
901 cccaagcaat ccacctgcct cagccttcca aaagtgtctg gattacaggc gtgagccacc
961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctcctgctc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctggggggaa accgaagggt
601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagtg ctgttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaagggggc attccgtctg taccaacccc
781 agtgacaagt ggggtccagga ctatatcaag gacatgaagg agaactgagt gaccagaag
841 ggggtggcga ggcacagctc agagacataa agagaagatg ccaaggcccc ctctccacc
901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL     Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL     Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            gene            1..1430
                        /gene="HCC-4"
            CDS              1..363
                        /gene="HCC-4"
                        /note="CC or beta chemokine family member"
                        /codon_start=1
                        /product="IL-10-inducible chemokine"
                        /db_xref="PID:g2581781"

```

/translation="MKVSEALSLVLILIITSASRSQPKVPEWVNTPTSCCLKYIEK

VLPRRLVVG YRKALNCHLP AIFVTKR NREVCTNP NDDWVQEYIKDPNL PLLPTRNLS
TVKIIITAKNGQPQLLSQ"

BASE COUNT 401 a 351 c 293 g 385 t

ORIGIN

```

1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttctgctc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
361 tgatgaccag gcttttagtg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattaggg tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaaataag gagaagtatt tcgaatatat tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtag gctcttttat ttttatatt atatttttat tttttgaga
601 taggtcttac tctgtcacc aggctggagt gcagtgggtg gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gcctcccag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt ttttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggc tcaaactcgt gtgcccaagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgac
901 tcttaataca cagaaaaata tatttcacat ccttctcctg ctctctttca attcctcact
961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaaagag cccatagaac tcttgatttt tctgttccat
1081 ctttatggat ttttctggat ctatattttc ttcaattatt ctttcatttt ataagtcaac

```

Vertebrata; Mammalia; Euthera; Primates; Catarrhini;
Hominidae;
Homo.
REFERENCE 1 (bases 1 to 821)
AUTHORS Hromas,R., Gray,P.W., Chantry,D., Godiska,R., Krathwohl,M.,
Fife,K., Bell,G.I., Takeda,J., Aronica,S., Gordon,M.,
Cooper,S.,
Broxmeyer,H.E. and Klemsz,M.J.
TITLE Cloning and characterization of exodus, a novel beta-chemokine
JOURNAL Blood 89 (9), 3315-3322 (1997)
MEDLINE 97275143
REFERENCE 2 (bases 1 to 821)
AUTHORS Hromas,R.A.
TITLE Direct Submission
JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
FEATURES
source Location/Qualifiers
1..821
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="Exodus-1"
/cell_type="islet"
/tissue_type="pancreas"
/dev_stage="adult"
CDS
43..330
/function="inhibits proliferation of hematopoietic
progenitors and HIV"
/codon_start=1
/product="chemokine exodus-1"
/db_xref="PID:g1778717"
/translation="MCCTKSLLLAALMSVLLHLHLCGESEASNFDCCLGYTDRIHHPKF
IVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKKVKNM"
variation 121..122
/note="insertion of an extra codon GCA at nt 121,
encoding for an alanine after the alanine at amino acid
position 26, represents the allelic difference of the
transcript isolated from macrophages"
BASE COUNT 258 a 134 c 156 g 273 t
ORIGIN
1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
61 ttgctcctgg ctgctttgat gtcagtgcgt ctactccacc tctgcggcga atcagaagca
121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
301 ctccctcagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tgggaattgga
361 catagcccaa gaacagaaag aaccttgcgt gggttggagg ttccacttgc acatcatgga
421 gggtttagtg cttatctaata ttgtgcctca cctggacttg tccaattaat gaagtgtgatt
481 catattgcat catagtttgc tttgtttaag catcacatta aagtgaact gtattttatg
541 ttattttatag ctgtaggttt tctgtgttta gctatttaata actaattttc cataagctat
601 tttggtttag tgcaaatgat aaaattatat ttggggggga ataagattat atggactttc
661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
781 ttgaaaataa agaaacaaaa agtgcttctg ttaaaaaaaa a
//
LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
ACCESSION U88320
NID g2196919
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Euthera;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 828)
AUTHORS Hromas,R., Kim,C.H., Klemsz,M., Krathwohl,M., Fife,K.,
Cooper,S.,

TITLE Schnizlein-Bick,C. and Broxmeyer,H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"
 /translation="MAQSLALSLLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV
 VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKSGCKRTERSQT PKGP"
 BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN
 1 ggcacgaggc agacatggct cagtcaactgg ctctgagcct ccttatcctg gttctggcct
 61 ttggcatccc caggacccaa ggcagtgatg gaggggctca ggactgttgc ctcaagtaca
 121 gccaaaggaa gattccccgc aaggttgtcc gcagctaccg gaagcaggaa ccaagcttag
 181 gctgctccat cccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
 241 cagacccaaa ggagctcttg gtgcagcagc tgatgcagca tctggacaag acaccatccc
 301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaag
 361 gaaaggggtc caaaggctgc aagaggactg agcggtcaca gaccctaaa gggccatagc
 421 ccagttagca gcctggagcc ctggagacc caccagcctc accagcgctt gaagcctgaa
 481 cccaagatgc aagaaggagg ctatgctcag gggccctgga gcagccacc catgctggcc
 541 ttgccacact ctttctcctg ctttaaccac ccatctgca ttcccagctc tcaccctgca
 601 tggctgagtc tgcccacagc aggccaggtc cagagagacc gaggaggag agtctccag
 661 ggagcatgag aggaggcagc aggactgtcc ccttgaagga gaatcatcag gaccctggac
 721 ctgatacggc tcccagtagc accccacctc ttccctgtaa atatgattta tacctaactg
 781 aataaaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaaaa
 //
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas,R.A., Gray,P., Klemsz,M., Fife,K. and Broxmeyer,H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502


```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
CDS
120..416
/note="Mip-3alpha/ELC/CKbeta11"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

/translation="MALLLALSLLVLTSPAPTLSGTNDACCLSVTQKPIPGYIVR

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPDPQWVERIIQRLQRTSAKMKRRSS"
BASE COUNT      113 a      170 c      121 g      98 t
ORIGIN
    1  ctcacacctt gcatttcacc cctgcatccc atgcgccctg cagcctcaca cagatcctgc
   61  acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
  121  tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
  181  gtggcaccac tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
  241  acatcgtgag gaatttcac taccttctca tcaaggatgg ctgcagggtg cctgctgtag
  301  tgttcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
  361  gcacatcca gagactgcag aggacctcag ccaagatgaa gcgccgcagc agttaacctc
  421  tgaccgtgca gagggagccc cgagtccgag tcaagcattg tgaattatta ctaactggga
  481  acgaggacag aaggaaggac ag

//

LOCUS      HSU86358      879 bp      mRNA      PRI      11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION  U86358
NID        g2388626
KEYWORDS
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 879)
AUTHORS    Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P., Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
and
            Zlotnik,A.
TITLE      TECK: a novel cc chemokine specifically expressed by thymic
            dendritic cells and potentially involved in T cell development
JOURNAL    Immunology 7, 291-301 (1997)
REFERENCE  2 (bases 1 to 879)
AUTHORS    Vicari,A.P. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901
            California Ave., Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
    source      1..879
                 /organism="Homo sapiens"
                 /db_xref="taxon:9606"
                 /chromosome="4"
                 /tissue_type="thymus"
    gene        1..879
                 /gene="TECK"
    CDS         1..453
                 /gene="TECK"
                 /codon_start=1
                 /product="chemokine"
                 /db_xref="PID:g2388627"

/translation="MNLWLLACLVLGAWAPAVHTQGVFEDCLAYHYPIGWAVLR

RAWTYRIQEVSGSNCNLPAAIFYLPKRHRKVCNPKSREVQRAMKLLDARNKVFAKLHH
NMQTFQAGPHAVKKLSSGNSKLSSSKFSNPISSSKRNVSLLISANSGL"
BASE COUNT      191 a      264 c      218 g      206 t

```

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctgggt gccggcttcc tgggagcctg ggcccccgct
61 gtccacacccc aaggtgtctt tgaggactgc tgccctggcct accactaccc cattgggtgg
121 gctgtgtctcc ggcgcgcctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct cccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggaggtgc agagagccat gaagctcctg gatgctcgaa ataagggttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
481 acaggagggg ccggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgcctctgtc ttttgggtca agtcttaatc cctgcacctg agttggctct cctctgcac
601 cccaccacc tcctgcccggt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgccgctcc ggggaacagc acaatcctgg gcagccagt gctcttgtag agaaaactta
721 ggataacctc ctcactttct gtttcttgcc gtccaccccg ggccatgcca gtgtgtcctc
781 tgggtccctt ccaaaaatct gggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE     Homo sapiens cDNA to mRNA.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
            Homo.
REFERENCE  1 (bases 1 to 852)
AUTHORS   Nomiya, H.
TITLE     Direct Submission
JOURNAL   Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE  2 (bases 1 to 852)
AUTHORS   Nagira, M., Imai, T., Hieshima, K., Kusuda, J., Ridanpaa, M.,
Takagi, S.,
TITLE     Nishimura, M., Kakizaki, M., Nomiya, H. and Yoshie, O.
            Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL   Unpublished (1997)
FEATURES   Location/Qualifiers
            source      1..852
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS         59..463
                        /codon_start=1
                        /product="SLC"
                        /db_xref="PID:d1022673"
                        /db_xref="PID:g2335035"

/translation="MAQSLALSLILVLAFGIPRTQSGDGAQDCCLKYSQRKIPAKV
VRSYRKQEPSLGCISIPAILFLPRKRSQAELCADPKELWVQQLMOHLDKTPSPQKPAQG
CRKDRGASKTGKKKGKSGCKRTSQTTPKGP"
            mat_peptide  <107..460
                        /product="mature ELC"
            polyA_site   823..828
BASE COUNT  205 a      279 c      217 g      151 t
ORIGIN
1 cttgcagctg cccacctcac cctcagctct ggctctttac tcacctcta ccacagacat
61 ggctcagtcg ctggctctga gcctccttat cctggttctg gcctttggca tccccaggac
121 ccaaggcagt gatggagggg ctcaggactg ttgcctcaag tacagccaaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatcccgag
241 tatcctgttc ttgccccgca agcgctctca ggcagagcta tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcca tagcccagtg agcagcctgg
481 agccctggag accccaccag cctcaccacg gcttgaagcc tgaaccacag atgcaagaag
541 gaggtatgc tcaggggccc tggagcagcc accccatgct ggccttgcca cactcttctt
601 cctgctttaa ccacccatc tgcattccca gctctaccct gcatggctga gctgcccaca
661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctcccagct
781 acaccaccac tcttccttgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
841 cttcccaccc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS   .
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocyte chemoattractant human CC chemokine, with
myelosuppressive
            activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS     Youn,B.S. and Kwon,B.S.
TITLE      Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
Science     Bldg., Indianapolis, IN 46202, USA
FEATURES    Location/Qualifiers
      source      1..1481
                  /organism="Homo sapiens"
                  /db_xref="taxon:9606"
                  /chromosome="17"
      5'UTR       1..34
      CDS         35..397
                  /note="Mtn-1; LMC; lymphocyte and monocyte
chemoattractant
                  CC chemokine"
                  /codon_start=1
                  /product="monotactin-1"
                  /db_xref="PID:g3395776"

```

/translation="MKVSEALSLLVLILIITSASRSQPKVPEWVNTPTSCCLKYYEK

VLPRRLVVGYRKALNCHLPALIFVTKRNREVCTNPNDWVQEIYKDPNLPLLPTRNLS
TVKIITAKNGQPQLLNSQ"

```

3'UTR      398..1481
BASE COUNT 412 a    362 c    302 g    405 t
ORIGIN

```

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgct ctcacacctta tcattacttc ggcttctcgc agccagccaa aagttcctga
121 gtgggtgaac accccatcca cctgctgcct gaagtattat gagaaagtgt tgccaaggag
181 actagtgggt ggatacagaa aggccctcaa ctgtcacctg ccagcaatca tcttcgtcac
241 caagagggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
301 ggatcccaac ctacctttgc tgccctaccag gaacttgctc acggttaaaa ttattacagc
361 aaagaatggt caacccacgc tcctcaactc ccagtgtatga ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt atttcgaata
541 tttttcfaat ctttagagga aataccaaag ttaagggacg tgggcagagg tacgctcttt
601 tatttttata tttatatatt tttttttt agatagggtc ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccacctccca
721 ggctcaagtg atcctccac cccaccctcc cgagttagct ggactacagg ctgtgcgccac
781 cacacctggc taatttttgt atttttggtg gagacgggat tctaccatgt tgcccaggct

```

```

841 ggtctcaaac tcgtgtgcc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc cttccagatg atctttgcc tctgggtctt gaccattaa
1081 gagccccata gaactcttga ttttctctgt ccatctttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttct
1261 caggggtggca ggggtacaga agtgcctgat tggttttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
1381 aagaaagggg atgagacacg gctagggtta actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc ccttatttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      HSRNAATAC      557 bp      RNA      PRI      06-JUL-1995
DEFINITION H.sapiens mRNA for ATAC protein.
ACCESSION  X86474
NID        g895846
KEYWORDS   ATAC gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 557)
AUTHORS    Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and KroczeK,R.A.
TITLE      Cloning of ATAC, an activation-induced, chemokine-related
molecule  exclusively expressed in CD8+ T lymphocytes
JOURNAL     Eur. J. Immunol. 25 (6), 1744-1748 (1995)
MEDLINE     95339892
REFERENCE  2 (bases 1 to 557)
AUTHORS      KroczeK,R.A.
TITLE       Direct Submission
JOURNAL     Submitted (20-APR-1995) R.A. KroczeK, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES    Location/Qualifiers
  source     1..557
             /organism="Homo sapiens"
             /db_xref="taxon:9606"
             /tissue_type="peripheral blood"
             /cell_type="lymphocyte"
             /chromosome="1"
             /map="q23"
  gene       25..369
             /gene="ATAC"
  CDS        25..369
             /gene="ATAC"
             /codon_start=1
             /product="CD8+T cell specific protein"
             /db_xref="PID:g895847"
             /db_xref="SWISS-PROT:P47992"

/translation="MRLILALLGICSLTAYIVEGVGSEVSKRTCVSLTTQRLPVSR
IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVRSMRKSNTNRNMIQTKPTGT
      QQSTNTAVTLTG"
  polyA_signal 469..474
  polyA_signal 534..539
BASE COUNT  157 a    139 c    112 g    149 t
ORIGIN
      1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
      61 tctctcactg catacattgt ggaagggtga gggagtgaag tctcagataa gaggacctgt
      121 gtgagcctca ctaccagcgc actgccggtt agcagaatca agacctacac catcacggaa
      181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
      241 caagccacat ggggtgagaga cgtgggtcagg agcatggaca ggaaatccaa caccagaaat
      301 aacatgatcc agaccaagcc aacaggaacc cagcaatcga ccaatacagc tgtgactctg
      361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttcactttac
      421 acgctcatgg actgagttta tactcgctt ttatgaaagc actgcatgaa taaaattatt
      481 cctttgtatt tttactttta aatgtcttct gtattcactt atatgttcta attataaat
      541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete
 cds.
 ACCESSION U85767
 NID gl916249
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-chemokines as inhibitors of two distinct classes of myeloid progenitors
 J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
 Keywest Ave., Rockville, MD 20850, USA
 FEATURES
 source Location/Qualifiers
 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:gl916250"
 /translation="MKVSVAAALSCMLVLTALGSQARVTKDAETEFMMSKLPENPVLL
 DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
 QVCMRMLKLOTRIKTRKN"
 BASE COUNT 164 a 143 c 117 g 139 t
 ORIGIN
 1 ctcagccagc cctgcctgcc caccaggagg atgaaggctc cctgggctgc cctctcctgc
 61 ctcatgcttg ttactgccct tggatcccag gcccggtgca caaagatgc agagacagag
 121 ttcattgatgt caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
 181 agtgctgact gctgcatctc ctacacccca cgaagcatcc cgtgttcact cctggagagt
 241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttctctac caagaagggg
 301 cgagctttct gtgccaaccc cagtgtataag caagttcagg ttgcatgag aatgctgaag
 361 ctggacacac ggatcaagac caggaagaat tgaactgtc aagggtgaag gacacaagtt
 421 gccagccacc aactttcttg cctcaactac cttcctgaat tattttttta agaagcattt
 481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
 541 aaaaaaaaaa aaaaaaaaaa aaa
 //

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete
 cds.
 ACCESSION U85768
 NID gl916251
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors
J. Exp. Med. (1997) In press

JOURNAL
REFERENCE 2 (bases 1 to 360)
AUTHORS Li, H. and Patel, V.P.
TITLE Direct Submission
JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
Keywest Ave., Rockville, MD 20850, USA

FEATURES
source Location/Qualifiers
1..360
/organism="Homo sapiens"
/db_xref="taxon:9606"

CDS
1..360
/note="myeloid progenitor inhibitory factor-2"
/codon_start=1
/product="MPIF-2"
/db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIIPSGSVVIPSPCCMFFVSKRIPE
NRVVSQYLSSRSTCLKGGVIFTTKKGQFCGDPKQEWVQRYMKNLDAKQKKASPRARA
VAVKGPVQRYPGNQTTTC"

BASE COUNT 85 a 106 c 96 g 73 t
ORIGIN
1 atggcaggcc tgaatgacct agtaaccagc cttctgttcc ttggtgtctg tgcccaccac
61 atcatcccta cgggctctgt ggtcataacc tctcctgct gcatgttctt tgtttccaag
121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgctcaag
181 ggaggagtga tcttcaccac caagaaggc cagcagttct gtggcgacct caagcaggag
241 tgggtccaga ggtacatgaa gaacctggac gccaagcaga agaaggcttc ccctaggggc
301 agggcagtgg ctgtcaaggg ccctgtccag agatatactg gcaaccaaac cacctgctaa
//

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA,
complete cds.
ACCESSION L36034
NID g1220363
KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
homologue; alpha-chemokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1847)
AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
Shinohara, T. and Honjo, T.
TITLE Structure and chromosomal localization of the human stromal
cell-derived factor 1 (SDF1) gene
JOURNAL Genomics 28 (3), 495-500 (1995)
MEDLINE 96039262

FEATURES
source Location/Qualifiers
1..1847
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="h5"
/cell_line="FLEB14-14"

sig_peptide 80..142
/gene="SDF1a"

CDS 80..349
/codon_start=1
/product="pre-B cell stimulating factor homologue"
/db_xref="PID:g1220364"

/translation="MNAKVVLVLVLTALCLSDGKPVSLSYRCPFRFFESHVARANV
KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIEYLEKALNK"

gene 80..346
/gene="SDF1a"

mat_peptide 143..346

```

/ gene="SDF1a"
/ product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
1  tctccgctcag cgcgattgcc cgctcggcgt cgggcccccg acccgtgctc gtccgccccg
61  cgcgccccgc gcccgcgcca tgaacgcca ggtcgtggtc gtgctgggcc tcgtgctgac
121 cgcgctctgc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
361 aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttgtagg agatgaaagg
421 gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
481 cattgatctg ggcgcgggcc tgagggtttg agcatttaga ccttgcatat atagcatagc
541 gtatgatatt gcagcttata ttcatccatg cctgtacctt gtgcacgttg gaacttttat
601 tactgggggt tttctaagaa agaaattgta ttatcaacag cattttcaag cagttagttc
661 cttcatgata atcacatca tcatcattct cattctcatt ttttaaatca acgagtactt
721 caagatctga atttggcttg tttggagcat ctctctgctt cccctgggga gtctggggac
781 agtcagggtg tggcctaaca gggagctgga aaaagtgtcc ttcttcaga cactgaggct
841 cccgcagcag cgccccctcc aagaggaagg cctctgtggc actcagatac cgactggggc
901 tggggcgccg ccactgcctt cactcctctt ttcaaacctc agtgattggc tctgtgggct
961 ccatgtagaa gccactatta ctgggactgt ctcagagacc cctctccag ctattcctac
1021 tctctccccg actccgagag catgcttaat cttgcttctg ctctctcatt ctgtagcctg
1081 atcagcgccg caccagccgg gaagaggggt attgctgggg ctcgtgccct gcactccctt
1141 cctcccaggg cctgccccac agctcggggc ctctgtgaga tccgtctttg gcctctccca
1201 gaatggagct ggccctctcc tggggatgtg taatgggtccc cctgcttacc cgcaaaagac
1261 aagtcctttac agaatacaat gcaattttaa atctgagagc tcgcttgagt gactgggttt
1321 gtgattgcct ctgaaagccta tgtagcccat ggaggcacta acaaaactctg aggtttccga
1381 aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccaactacccc ctctgaagc
1441 cacagcaggg gttcagggtt caatcagaac tgttggcaag gtgacatttc catgcataga
1501 tgcgatccac agaaggctct ggtgggtatt gtaacttttt gcaaggcatt tttttatata
1561 tatttttgtg cacatttttt tttagcattc tttagaaaac aaatgtattt caaaatatat
1621 ttatagtcga acaagtcat tatatgaatg agagccatat gaatgtcagt agtttatact
1681 tctctattat ctcaaaacta tggcaatttg taaagaaata tatatgatat ataaatgtga
1741 ttgcagcttt tcaatgttag ccacagtgtg ttttttctact tgtactaaaa ttgtatcaaa
1801 tgtgacatta tatgcactag caataaaatg ctaattgttt catggtg

```

//

```

LOCUS      HUMSDF1B      3524 bp      mRNA      PRI      26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
            complete cds.
ACCESSION  L36033
NID        gl220365
KEYWORDS   intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 3524)
AUTHORS    Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
            Shinohara,T. and Honjo,T.
TITLE      Structure and chromosomal localization of the human stromal
            cell-derived factor 1 (SDF1) gene
JOURNAL    Genomics 28 (3), 495-500 (1995)
MEDLINE    96039262
FEATURES   Location/Qualifiers
            source          1..3524
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /clone="h17"
                        /cell_line="FLEB14-14"
            sig_peptide     80..142
                        /gene="SDF1b"
            CDS             80..361
                        /codon_start=1
                        /product="pre-B cell stimulating factor homologue"
                        /db_xref="PID:gl220366"

```

```

/translation="MNAKVVVVVLVLVTALCLSDGKPVLSYRCPFRFFESHVARANV
            KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM"

```

```

gene      80..358
          /gene="SDF1b"
mat_peptide 143..358
          /gene="SDF1b"
          /product="pre-B cell stimulating factor homologue"
BASE COUNT 903 a 886 c 793 g 942 t
ORIGIN
1  tctccgtcag cgcattgcc cgctcggcgt cggccccccg acccgtgctc gtccgcccgc
61  ccgccccccc gcccgcgcca tgaacgccaa ggtcgtggtc gtgctgggtc tctgtctgac
121  cgcgctctgc ctacgcgacg ggaagcccggt cagcctgagc tacagatgcc catgccgatt
181  cttcgaaagc catgttgcca gagccaacgt caagcatctc aaaaattctca acactccaaa
241  ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301  gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
361  agaggggtcag acgcctgagg aacccttaca gtaggagccc agctctgaaa ccagtgttag
421  ggaagggcct gccacagcct cccctgccag ggcagggccc caggcattgc caagggcttt
481  gttttgcaca ctttgccata ttttcaccat ttgattatgt agcaaaatca atgacattta
541  tttttcattt agtttgatta ttcagtgtca ctggcgacac gtagcagctt agactaaggc
601  cattattgta cttgccttat tagagtgtct ttcacaggag ccactcctct gactcagggc
661  tcttgggttt tgtattctct gagctgtgca ggtggggaga ctgggctgag ggagcctggc
721  cccatgggtca gccctagggt ggagagccac caagagggac gcctgggggt gccaggacca
781  gtcaacctgg gcaaaagccta gtgaaggctt ctctctgtgg gatgggatgg tggagggcca
841  catggggagc tcaccccctt ctccatccac atgggagccg ggtctgcctc tctctggagg
901  gcagcagggc tacctgagc tgaggcagca gtgtgaggcc agggcagagt gagaccacgc
961  cctcatcccg agcacctcca catcctccac gttctgtctc tcatctcttg tctcatccat
1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaagct
1081 ttcattgtaa ctgtgcacca agcaggaaat gaaaatgtct tgtgttacct gaaaacactg
1141 tgcacatctg tgtcttctgt ggaatattgt ccattgtcca atcctatggt tttgttcaaa
1201 gccagcgtcc tctctctgta ccaatgtctt gatgcatgca ctgttcccc ctgtcagccg
1261 ctgagcgagg agatgctcct tgggcccttt gagtgcagtc ctgatcagag ccgtggctct
1321 ttgggggtgaa ctaccttggt tccccactg atcacaaaaa catgggtgggt ccatgggcag
1381 agcccaaggg aattcgggtg gcaccagggt tgaccccgag gatttgctgc cccatcagtg
1441 ctccctcaca tgtcagtacc ttcaaaactag ggccaagccc agcactgtct gaggaaaaaca
1501 agcattcaca acttgttttt ggtttttaaa acccagtcca caaaaataacc aatcctggac
1561 tccaagattc ttcccaatt ccatctaac ctcatctct caccatttg gcaatggcat
1621 catctcctgc ctctcctctg ggccctctct gctctgcgtg tcacctgtgc ttcggggcct
1681 tcccacagga catttctcta agagaacaat gtgctatgtg aagagttaag caacctgcct
1741 gccatttggg gtgttccctt cccactgagg gcagtcgata gagctgtatt aagccactta
1801 aaatgttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgttt ttcattcagt
1861 cttacgaata cttttgcctt ttgattaaa actccagtta aaaaaaattt taatgaagaa
1921 agtggaatac aaggaagtca aagcaaggaa actatgtaac atgtagggaag taggaagtaa
1981 attatagtga tgaatctctg aattgtaact gttcgtgaat ttaataatct gtagggtaat
2041 tagtaacatg tgttaagtat tttcataagt atttcaaat ggagcttcac gcagaaggc
2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc cagctatggt
2161 atattgaaaa aatagagcct gagggatctt tactagtatt aaagatacag aactctttca
2221 aaaccttttg aaattaacct ctactatac cagtataatt gagttttcag tggggcagtc
2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttggg tgtacctgcc
2341 cccaatccat gaaccaagac cattgaattc ttgggtgagg aaacaaacat gaccctaaat
2401 ctgactaca gtcaggaaaag gaatcatttc tatttctct ccatgggaga aaatagataa
2461 gagttagaac tgcagggaaa attatttgca taacaattcc tctactaaca atcagctcct
2521 tcttgagagc tgcccagcta aagcaaatat catttaataa cagtcttcca tttgcaaggg
2581 aaaagtctct tgaatccga atctcttttt gctttcgaa tgctagtcaa gtgcgtccac
2641 gagctgttta ctagggtacc ctcatctgtc cctccgggac ctggtgctgc ctctacctga
2701 cactcccttg ggtccctgt aacctcttca gaggccctcg ctgccagctc tgtatcagga
2761 cccagaggaa ggggccagag gctcgttgac tggctgtgtg ttgggattga gtcgtgcca
2821 cgtgtatgtg ctgtggtgtg tccccctctg tccaggcact gagataccag cgaggaggct
2881 ccagagggca ctctgcttgt tattagagat tacctcctga gaaaaaagct tccgcttggg
2941 gcagaggggc tgaatagcag aaggttgcac ctccccaac cttagatgtt ctaagtcttt
3001 ccattggatc tcattggacc ctcccatggt gtgatcgtct gactggtgtt atcaccgtgg
3061 gctccctgac tgggagtga tcgcctttcc cagggtgtac acccttttcc agctggatga
3121 gaatttgagt gctctgtacc ctctacagag ctccctgac tcattctgaa ggagcccat
3181 tcttgggaaa tattccctag aaacttccaa atcccctaag cagaccactg ataaaaccat
3241 gtgaaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
3301 cagtgttaaa tgtgatgaat actgtatttt gtattgtttc aagtgcactc cccagataat
3361 gtgaaaaatg tccaggagaa ggccaattcc tatacgagc gtgctttaaa aaataataa
3421 gaaacaactc tttgagaaac aacaatttct actttgaagt cataccaatg aaaaaatgta
3481 tatgcactta taattttcct aataaagttc tgtactcaaa tgta

```

//

```

LOCUS      HSJ002211 663 bp mRNA PRI 11-MAR-1998
DEFINITION Homo sapiens cDNA for a CXC chemokine.
ACCESSION AJ002211

```


NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler,D.F., Loetscher,M., Roos,R.S., Clark-Lewis,I.,
 Baggiolini,M.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser,B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"
 /translation="MKFISTSLLLMLLVSSLSPVQGVLEVYTSLRRCVQESSVFIP
 RRFIDRIQILPRGNGCPRKEIIVWKKNSIVCVPQAEWIQRMMEVLRKRSSSTLPVP
 VFKRKIP"
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN
 1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcattctga catctctgct
 61 tctcatgctg ctggctcagca gcctctctcc agtccaagggt gttctggagg tctattacac
 121 aagcttgagg tgtagatgtg tccaagagag ctcagtcttt atccctagac gcttcattga
 181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
 241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
 301 agtattgaga aaaagaagtt cttcaactct accagttcca gtgtttaaga gaaagattcc
 361 ctgatgctga tatttccact aagaacacct gcattcttcc cttatccctg ctctgggatt
 421 ttagttttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaaataagg
 481 catgaggact atgtaaaaat aaccttgacg gagctggatg gggggccaaa ctcaagcttc
 541 tttcactcca caggcacctc attntacact tgggggtttt gcnttctttn tttctcagg
 601 gggggggaaa gtttcttttg gaaantagtt nttccagttt ttaggtatta cagggttntt
 661 ttt
 //
 LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber,J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of
 USA
 Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
 USA
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES Location/Qualifiers
 source 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLGLGIILLVLIGVQGPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQVQTCNLPDSADVKEIKKWEKQVSQKKKQKNG
 KKHQKKKVLKVRKSQRSRQKKT

BASE COUNT 755 a 581 c 457 g 752 t
 ORIGIN

```

1 atccaatata ggagtgcatt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctggttctg attggagtgc aaggaaaccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtggggaga aacagggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtctg aaaaatctcaa cgttctcgtc aaaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaag gcttattaat ttgactagaa aattttaaac
541 attactctga aattgttaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt cttgtttctt ctaccaccca ccagttgaat ttcatcatgc
661 ttaaggccat gattttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcaacaacag ctgacctgga gagcagccct aggcctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaaag cctgttagca tgctggtagg ccaagcagtt
841 tgaaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatcacc
961 actggagatc accagtgtgt ggctttcaga gcctcctttc tggctttgga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccccct tgcctcatte
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt ctctctctca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc ttctcatct tgtccccaac accccacaga
1201 agtgccttct tctcccaatt catcctcact cagtcagct tagttcaagt cctgcctctt
1261 aaataaacct ttttgacac acaaattatc ttaaaactcc tgtttcactt ggttcagtag
1321 cacatgggtg aacactcaat gggttaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctccctgagg gcaagagcca cagtatattt ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctgggtac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttccaggacac tcaactacag gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacag agtgttgctc agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatatctct gactgttttt aaaaaatata cagtttaccg
1741 aaaaatcatat aatcttacia tgaaaaggac tttatagatc agccagtgcac caaccttttc
1801 ccaaccatac aaaaattcct ttcccgaag gaaaagggct ttctcaataa ggctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agtttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattggtg ccagttagc ctctgcagga tgtggaaacc ccttccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctataactca

```

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgcgtg cgggtggaga
2221 tccccccgga acgtcttata taatcatgaa actccctagt tccttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatattgt cactgacaca caggttataa
2401 tcatttatca tataatataca tacatgcata cactctcaaa gcaataaatt ttctacttca
2461 aaacagtatt gacttgtata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      HSHUMIG      2545 bp      RNA      PRI      16-NOV-1993
DEFINITION H.sapiens Humig mRNA.
ACCESSION  X72755 S60728
NID        g311375
KEYWORDS   chemokine; cytokine; Humig gene; secreted protein.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2545)
AUTHORS    Farber,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of         Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE  2 (bases 1 to 2545)
AUTHORS    Farber,J.M.
TITLE      HuMig: a new human member of the chemokine family of cytokines
JOURNAL    Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE    93236577
FEATURES   Location/Qualifiers
            source          1..2545
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /germline
                           /dev_stage="child"
                           /tissue_type="leukaemia"
                           /cell_type="monocyte"
                           /cell_line="THP-1"
                           /clone_lib="THP-1/IFN-gamma cDNA"
                           /clone="H-1-3"
            misc_feature    13..19
                           /note="cis-acting element; putative"
            gene            40..417
                           /gene="Humig"
            CDS             40..417
                           /gene="Humig"
                           /codon_start=1
                           /db_xref="PID:g311376"
                           /db_xref="SWISS-PROT:Q07325"

```

/translation="MKKSGVFLFLGLIILLVLIGVQGTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNQVQTCNLPDSADVKELIKKEKQVVSQKKQKNG
KKHQKKKVLKVRKSQRSRQKKTT"

BASE COUNT 755 a 581 c 457 g 752 t
ORIGIN

```

1 atccaataca ggagtgcatt ggaactccat tctatcacta tgaagaaaag tgggtgtctt
61 ttccctcttg gcatcatctt gctgggtctg attggagtg c aaggaacccc agtagtgaga
121 aaggggtcgt gttcctgcat cagcaccaac caaggggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtggggaga aacagggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagttc tgaaggttcg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga gtagggcata taatacaaaag gcttattaat ttgactagaa aattttaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt cttgttctt ctaccacca caggttgaat ttcattatgc
661 ttaaggccat gattttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcaaacag ctgcctggaa gagcagccct aggtctccac gtactgcagc ctccagagag
781 tatctgagga acatgtcagc aagtcctaag cctgttagca tgctgggtgag ccaagcagtt

```

```

841  tgaaattgag  ctggacctca  ccaagctgct  gtggccatca  acctctgtat  ttgaatcagc
901  ctacaggcct  cacacacaat  gtgtctgaga  gattcatgct  gattgttatt  gggatcacc
961  actggagatc  accagtgtgt  ggctttcaga  gcctccttcc  tggccttgga  agccatgtga
1021  ttccatcttg  cccgctcagg  ctgaccactt  tatttctttt  tgttccccct  tgttccattc
1081  aagtcagctc  ttctccatcc  taccacaatg  cagtgccttt  cttctctcca  gtgcacctgt
1141  catatgctct  gatttatctg  agtcaactcc  tttctcatct  tgtccccaac  accccacaga
1201  agtgctttct  tctcccaatt  catcctcact  cagtccagct  tagttcaagt  cctgcctctt
1261  aaataaacct  ttttggacac  acaaatattc  ttaaaactcc  tgtttcactt  ggttcagtac
1321  cacatgggtg  aacactcaat  ggtaactaa  ttcttgggtg  tttatcctat  ctctccaacc
1381  agattgtcag  ctcttgagg  gcaagagcca  cagtatatct  ccctgtttct  tccacagtgc
1441  ctaataatac  tgtggaacta  gggttttaata  attttttaat  tgatgttggt  atgggcagga
1501  tggcaaccag  accattgtct  cagagcaggt  gctggctctt  tcctggctac  tccatgttgg
1561  ctagcctctg  gtaacctctt  acttattatc  ttcaggacac  tcactacagg  gaccagggat
1621  gatgcaacat  ccttgtcttt  ttatgacagg  atgtttgctc  agcttctcca  acaataagaa
1681  gcacgtggta  aaacacttgc  ggatattctg  gactgttttt  aaaaaatata  cagtttaccg
1741  aaaatcatat  aatcttaca  tgaaaaggac  tttatagatc  agccagtgc  caaccttttc
1801  ccaaccatac  aaaaattcct  ttcccggaag  gaaaagggtc  ttctcaataa  gcctcagctt
1861  tctaagatct  aacaagatag  ccaccgagat  ctttatcgaa  actcatttta  ggcaaatatg
1921  agttttattg  tccgtttact  tgtttcagag  tttgtattgt  gattatcaat  taccacacca
1981  tctcccatga  agaaaggga  cggtagaagta  ctaagcgcta  gaggaagcag  ccaagtcggt
2041  tagtgaagc  atgattggtg  cccagttagc  ctctgcagga  tgtggaacc  tcctccagg
2101  ggaggttcag  tgaattgtgt  aggagaggtt  gtctgtggcc  agaatttaaa  cctatactca
2161  ctttcccaaa  ttgaatcact  gctcacactg  ctgatgattt  agagtgtctg  ccggtggaga
2221  tcccaccgga  acgtcttctc  taatcatgaa  actccctagt  tccttcatgt  aacttccctg
2281  aaaaatctaa  gtgtttcata  aatttgagag  tctgtgacct  acttaccttg  catctcacag
2341  gtagacagta  tataactaac  aaccaaagac  tacatatgtt  cactgacaca  cacgttataa
2401  tcatttatca  tatataata  tacatgcata  cactctcaaa  gcaaataatt  tttcacttca
2461  aaacagtatt  gacttgata  ccttctaatt  tgaaatattt  tctttgttaa  aatagaatgg
2521  tatcaataaa  tagaccatta  atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      A genetic selection for isolating cDNAs encoding secreted
proteins
JOURNAL    Gene 198 (1-2), 289-296 (1997)
MEDLINE    98036061
REFERENCE  2 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES   Location/Qualifiers
            source          1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
blood
            gene            mononuclear cells"
                        1..995
                        /gene="H174"
            CDS              88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```

```

/db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
IEKASIMYPSNNDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"
BASE COUNT      382 a      170 c      194 g      249 t
ORIGIN
    1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
   61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggct
  121 gtgatattgt gtgctacagt tgttcaaggc ttcccatgt tcaaaaggag acgctgtctt
  181 tgcataggcc ctggggtaaa agcagtgaag gtggcagata ttgagaaagc ctccataatg
  241 taccacaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaaagga
  301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
  361 aagaattttt aaaaatatca aaacatatga agtcctggaa aaggggcatct gaaaaacctt
  421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
  481 ttctatgggt ttgtgacttt caacttttgt acagttatgt gaaggatgaa aggtgggtga
  541 aaggacaaa aacagaaata cagtcttcct gaatgaatga caatcagaat tccactgccc
  601 aaaggagtcc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctggttac
  661 catcggagtt tacaagtgct ttacacgttc ttacttgttg tattatacat tcatgcattt
  721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgtga ctatgagaac
  781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatga ctatctgttg
  841 ttacagtggg gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
  901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
  961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc

//

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W.; Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
            novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL     J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE     98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS     Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL     Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
            Eastern
            Point Road, Groton, CT 06340, USA
FEATURES   Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1
                        /product="interferon stimulated T-cell alpha
                        chemoattractant precursor"
                        /db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKVAD
IEKASIMYPSNNDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
            /evidence=not_experimental

```

```

                /product="interferon stimulated T-cell alpha
                chemoattractant"
BASE COUNT      487 a    228 c    244 g    411 t    1 others
ORIGIN
1   ctcttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61  aaaaacaaac tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagtgtgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtcttgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg tttgtgact
481 ttcaactttt gtacagttaa gtgaaggatg aaaggtgggt gaaaggacca aaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt gggtacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gacaatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcacgggtct taatttgatg tttttcaact tttatcatt
1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatate ttggacacat ttgaaataca aaatgtttt gtctaccaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G. and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel      non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL    J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE    98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL    Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern    Point Road, Groton, CT 06340, USA
FEATURES   Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1
                        /product="interferon stimulated T-cell alpha
                        chemoattractant precursor"
                        /db_xref="PID:g3219693"

```

```

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide      133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT      487 a      228 c      244 g      411 t      1 others
ORIGIN
    1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
   61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgtctaca
  121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc ttgtcatagg cctgggggta
  181 aaagcagtga aagtggcaga tattgagaaa gctccataa tgtaccaag taacaactgt
  241 gacaaaatag aagtgtattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
  301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
  361 caaacatat gaagtcctgg aaaaaggcat ctgaaaaacc tagaacaagt ttaactgtga
  421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
  481 ttcaactttt gtacagttat gtgaaggatg aaagtggtgg gaaaggacca aaaacagaaa
  541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
  601 aatgggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
  661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
  721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
  781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
  841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
  901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
  961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
 1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgacat
 1081 atttcataac caaattagca gcaccggctc taatttgatg tttttcaact tttattcatt
 1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
 1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaaa
 1261 gaaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
 1321 tgtctcttag aaaaatacat aatctaata aaaaaaaaaa aaaaaaaaaa a

//

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
            non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL    J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE    98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL    Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
            Point Road, Groton, CT 06340, USA
FEATURES
            Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1

```

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVIIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgaagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgtctaca
121 gttgttcaag gcttccccat gttcaaaaga ggacgctgtc ttgtcatagg ccttggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaagg taacaactgt
241 gacaaaatag aagtgtattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagtgtgaa gaaagaattt ttaaaaatat
361 caaacatat gaagtctctg aaaaaggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttaa gtgaaggatg aaagtgagg gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatgggatttc taggaaaagc taccttaaga aaggctgggt accatcgagg tttacaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgtatat tactatctgt gggtacagtg gagacattga
841 cattattact ggagtcgaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcattcattt gtttgtttta taaccaattc attaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatagtgtg gtttactgta ctttttgttt tgatccggtt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaa
1261 gaaaatgtt gaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaata caaaaaaaaa aaaaaaaaaa a

//

LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic
factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1560)
AUTHORS Matsushima,K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer
Institute,,
Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima,K., Morishita,K., Yoshimura,T., Lavu,S.,
Kobayashi,Y.,
Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil
chemotactic factor (MDNCF) and the induction of MDNCF mRNA by
interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES
source Location/Qualifiers
1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"

```



```

CDS          102..401
              /codon_start=1
              /product="MDNCF precursor (AA -27 to 72)"
              /db_xref="PID:g34519"
              /db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF"

HPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide  183..398
              /note="mat. MDNCF (AA 1 - 72)"
BASE COUNT   526 a    247 c    281 g    506 t
ORIGIN
    1 ctccataagg cacaacttt cagagacagc agagcacaca agcttctagg acaagagcca
    61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
   121 tggctctctt ggcagccttc ctgattttctg cagctctgtg tgaagggtgca gttttgccaa
   181 ggagtgtctaa agaacttaga tgtcagtgca taaagacata ctccaaacct ttccacccca
   241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
   301 ttgtaaagct ttctgatgga agagagctct gtctggacc caggaaaaac tgggtgcaga
   361 gggttgtgga gaagtttttg aagagggctg agaattcata aaaaaattca ttctctgtgg
   421 tatccaagaa tcagtgaaga tgccagtga acttcaagca aatctacttc aacacttcat
   481 gtattgtgtg ggtctgttgt aggggttgcca gatgcaatac aagattcctg gttaaatttg
   541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
   601 atgtaaagta ttattttatt gaattctaca aaaacaacaa ataattttta aatataagga
   661 ttttcctaga tattgcacgg gagaatatac aaatagcaaa attgggccaa gggccaagag
   721 aatatccgaa ctttaatttc aggaattgaa tgggtttgct agaattgtgat atttgaagca
   781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
   841 ggattttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtccctg
   901 ttccactgtg ccttggtttc tcttttattt ctaagtggaa aaagtattag ccaccatctt
   961 acctcacagt gatgttggtg ggacatgtgg aagcacttta agttttttca tcataacata
  1021 aattattttc aagtgttaact tattaaccta ttattatttt atgtatttat ttaagcatca
  1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
  1141 atgttatagt aaattttattt tatttttagat attaaatgat gttttattag ataaatttca
  1201 atcaggggtt ttagattaaa caaacaaaca attgggtacc cagttaaatt ttcatctcag
  1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
  1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgtctg
  1381 tgttgaatta cggataaatg agttagaact attaaaacag ccaaaactcc acagtcaata
  1441 ttagtaattt cttgctgggt gaaacttgtt tattatgtac aaatagattc ttataattt
  1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttta aaaaaaccgg

//

LOCUS      HSINFGER      1172 bp      RNA      PRI      21-MAR-1995
DEFINITION Human mRNA for gamma-interferon inducible early response gene
(with      homology to platelet proteins).
ACCESSION  X02530 M17752
NID        g33917
KEYWORDS   interferon response; signal peptide.
SOURCE      human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1172)
AUTHORS    Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE      Gamma-interferon transcriptionally regulates an early-response
gene
            containing homology to platelet proteins
JOURNAL     Nature 315 (6021), 672-676 (1985)
MEDLINE     85240552
REFERENCE  2 (bases 1 to 1172)
AUTHORS      Luster,A.D.
TITLE       Direct Submission
JOURNAL     Submitted (29-JUL-1986) to the EMBL/GenBank/DDBJ databases
COMMENT     Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES    Location/Qualifiers
            source          1..1172
                        /organism="Homo sapiens"
                        /strain="(U 937 histiocytic lymphoma cell line)"
                        /db_xref="taxon:9606"
            misc_RNA        1
                        /note="cap site"

```

sig_peptide 67..129
 /note="pot. signal peptide (aa-21 to -1)"
 CDS 67..363
 /note="early response precursor polypeptide (aa-21 to
 77)"
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTALICCLIFLTLSGIQGVPLSRVTRCTCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGEKRCNPNESKAIKNLLKAVSKEMSKRSP"

mat_peptide 130..360
 /note="mature early response polypeptide (aa 1-77)"
 old_sequence 1138..1141
 /note="ugaa was uga in [1]"
 /citation=[1]
 old_sequence 1146..1148
 /note="caa was ca in [1]"
 /citation=[1]
 misc_feature 1155..1160
 /note="pot. polyA signal"
 polyA_site 1172
 /note="polyA site"

BASE COUNT 384 a 231 c 208 g 349 t
 ORIGIN

```

1 gagacattcc tcaattgctt agacatatcc tgagcctaca gcagaggaac ctccagtctc
61 agcaccatga atcaaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcacacagcat tagtaataca
181 cctgttaatc caaggtcttt agaaaaactt gaaattattc ctgcaagcca attttgtcca
241 cgtgttgaga tcattgtctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
421 cctctcccat cacttcctta catggagtat atgtcaagcc ataattgttc ttagtttgca
481 gttacactaa aagggtgacca atgatggtca ccaaatcagc tgctactact cctgtaggaa
541 gggttaattgt catcatccta agctattcag taataactct accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtgga tgctctgacc ctgcttcaaa tattccctc
661 acctttccca tcttccaagg gtactaagga atctttctgc tttggggttt atcagaattc
721 tcagaatctc aaataactaa aagggtatgca atcaaatctg ctttttaaag aatgctcttt
781 acttcatgga cttccactgc catcctccca aggggcccac attctttcag tggctaccta
841 catacaattc caaacacata caggaaggta gaaatatctg aaaaatgtatg tgtaagtatt
901 cttatttaat gaaagactgt acaaagtata agtcttagat gtatatattt cctatatattg
961 tttcagtgta catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
1081 ttttcaataa aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
1141 aagatcaaaa ggtaataaaa gtaattataa ct

```

//

LOCUS SYNRP4A 225 bp DNA SYN 15-JUN-1989
 DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
 ACCESSION M20901
 NID g209285
 KEYWORDS platelet factor; platelet factor 4.
 SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
 ORGANISM artificial sequence
 artificial sequence.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Barone, A.D., Ghrayeb, J., Hammerling, U., Zucker, M.B. and
 Thorbecke, G.J.
 TITLE The expression in Escherichia coli of recombinant human
 platelet
 factor 4, a protein with immunoregulatory activity
 JOURNAL J. Biol. Chem. 263, 8710-8715 (1988)
 MEDLINE 88243725
 FEATURES Location/Qualifiers
 source 1..225
 /organism="artificial sequence"
 /db_xref="taxon:29278"
 CDS <1..>225
 /note="recombinant platelet factor 4"
 /codon_start=2

```

/translation="ASMEAEDGDLQCLCVKTTTSQVRPRHITSLEVIKAGPHCPTAQL
IATLKDGRKICLDLQAPLYKKI IKKLES GS"
BASE COUNT      59 a      59 c      51 g      56 t
ORIGIN          HindIII site.
      1 agcttctatg gaagctgaag aagacgggtga cctgcagtgc ctgtgcgtta aaactacttc
     61 tcagggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggtc cgcattgccc
    121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggg
    181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc
//

```

```

LOCUS          HUMGRO          1050 bp      mRNA          PRI          11-JUN-1993
DEFINITION      Human gro (growth regulated) gene.
ACCESSION      J03561
NID            g183622
KEYWORDS        gro gene; tumor cell.
SOURCE          Human bladder tumor cell (T24) cDNA to mRNA.
ORGANISM        Homo sapiens
                Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
                Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE       1 (bases 1 to 1050)
AUTHORS         Anisowicz,A., Bardwell,L. and Sager,R.
TITLE           Constitutive overexpression of a growth-regulated gene in
                transformed Chinese hamster and human cells
JOURNAL         Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
MEDLINE         88041072
COMMENT         Draft entry and computer-readable sequence kindly submitted by
                R.Sager (20-NOV-1987).
FEATURES        Location/Qualifiers
                source          1..1050
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
                sig_peptide     54..140
                                /note="signal peptide (put.); putative"
                CDS             54..377
                                /note="gro protein"
                                /codon_start=1
                                /db_xref="PID:g306806"

```

```

/translation="MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRQC
CLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPA SPIVKKII EKMLN
SDKSN"
mat_peptide     141..374
                /note="gro mature protein (put.); putative"
BASE COUNT      270 a      246 c      239 g      295 t
ORIGIN          52 bp upstream of NcoI site.
      1 ctgcgcagct ctccgcctcc tctcacagcc gccagacccg cctgctgagc cccatggccc
     61 gcgctgctct ctccgcctcc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
    121 tgctctcgtt agccgctggc cggcgcgtag caggagcgct cgtggccact gaactgcgct
    181 gccagtgctt gcagaccctg cagggaaatt accccaagaa catccaaagt gtgaacgtga
    241 agtcccccg accccactgc gcccaaaccg aagtcatagc cacactcaag aatgggcgga
    301 aagcttgctt caatcttgca tccccatag ttaagaaaat catcgaaaag atgctgaaca
    361 gtgacaaatc caactgacca gaaggagga ggaagctcac tgggtggctgt tccatgaagga
    421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
    481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctatttattt atttattcat
    541 tagttttgaa gattctatgt taatatttta ggtgtaaaaa aattaagggt atgattaaat
    601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
    661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgttctcc agtcattatg
    721 ttaatatctt tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
    781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
    841 actgtttaga tgaatgtcga ttgttattta ttgaaatgat ttcacagtgt gtggtcaaca
    901 tttctcatgt tgaactttta agaactaaaa tgttctaaat atcccttgga cattttatgt
    961 ttttcttgta aggcatactg ccttgtttaa tggtagtttt acagtgtttc tggcttagaa
   1021 caaaggggct taattattga tgttttcgga
//

```

```

LOCUS          HUMGROB5        1110 bp      mRNA          PRI          07-MAR-1995
DEFINITION      Human cytokine (GRO-beta) mRNA, complete cds.

```

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES
 source Location/Qualifiers
 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLLRVALLLLLLVAASRRRAAGAPLATELRQC

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNQKACLNPASPMVKKIIEKMLK
 NGKSN"

BASE COUNT 300 a 247 c 247 g 316 t
 ORIGIN

```

1 gacagagccc gggccacgga gctccttgcc agctctcttc ctgcacagc cgctcgaacc
61 gcctgctgag ccccatggcc cgcgccacgc tctccgccgc ccccgcaat ccccggtctc
121 tgcgggtggc gctgctgctc ctgctcctgg tggccgccag ccggcgcgca gcaggagcgc
181 cccctggccac tgaactgcgc tgccagtgc tgcagaccct gcagggaatt cacctcaaga
241 acatccaaag tgtgaagggtg aagtcctccg gaccccaactg cgcccaaac gaagtcatag
301 ccacactcaa gaatgggagc aaagcttgct tcaacccgc atcgcccatg gttaaagaaa
361 tcacgcgaaa gatgctgaaa aatggcaaat ccaactgacc agaaggaagg aggaagctta
421 ttggtggctg ttcctgaagg aggcctgccc ttacaggaac agaagaggaa agagagacac
481 agctgcagag gccacctggc ttgcgcctaa tgtgtttgag catacttagg agaagtcttc
541 tatttattta tttatttatt tatttggttg ttttagaaga ttctatgta atattttatg
601 tgtaaaataa ggttatgatt gaattctact gcacactctc ccattatatt tattgtttat
661 tttagggtcaa acccaagtta gttcaatcct gattcatatt taatttgaag atagaaggtt
721 tgcagatatt ctctagtcac ttgttaatat ttcttcgtga tgacatatca catgtcagcc
781 actgtgatag aggctgagga atccaagaaa atggccagta agatcaatgt gacggcaggg
841 aaatgtatgt gtgtctatgt tgtaactgta aagatgaatg tcagttgtta tttattgaaa
901 tgatttcaca gtgtgtgggc aacatttctc atgttgaagc ttttaagaact aaaatgttct
961 aaatatccct tggcatttta tgtctttctt gtaagatact gccttggtta atgtttaatta
1021 tgcagtgttt cctctgtgtg tagagcagag aggtttcgat atttattgat gttttcaca
1081 agaacaggaa aataaaatat ttaaaaatat
  
```

//

LOCUS HUMGROGS 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.

FEATURES Location/Qualifiers
 source 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"

/translation="MAHATLSAAPSNPRLRLVALLLLLLLVGSRRAAGASVVTELRCQC

LQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLKNGKKACLNPASPMVQKIIIEKILNK
 GSTN"

BASE COUNT	281 a	237 c	239 g	305 t	2 others	
ORIGIN	1 cacagccggg	tcgcaggcac	ctccccngcc	agctctcccg	cattctgcac	agcttcccga
	61 cgcgtctgct	gagccccatg	gcccacgcca	cgctctccgc	cgccccagc	aatccccggc
	121 tcctgcgggt	ggcgtgctg	ctcctgctcc	tggtgggcag	cgggcgcgca	gcaggagcgt
	181 ccgtgggtcac	tgaactgcgc	tgccagtgtc	tcgagacact	gcagggaatt	cacctcaaga
	241 acatccaaag	tgtgaatgta	aggteccccg	gacccactg	cgcccaaacc	gaagtcatag
	301 ccacactcaa	gaatgggaag	aaagcttgct	tcaacccgc	atcccccatg	gttcagaaaa
	361 tcactgaaaa	gatactgaac	aaggggagca	ccaactgaca	ggagagaagt	aagaagctta
	421 tcagcgtatc	attgacactt	cctgcagggt	ggtccctgcc	cttaccagag	ctgaaaaatga
	481 aaaagagaac	agcagctttc	tagggacagc	tggaaggga	cttaattgtg	ttgactattt
	541 cttacgagg	ttctacttat	ttatgtattt	atttttgaaa	gcttgtattt	taattattta
	601 catgctgtta	tttaaagatg	tgagtgtgtt	tcatacaaca	tagctcagtc	ctgattattt
	661 aattggaata	tgatgggttt	ttaatgtgtc	attaaactaa	tatttagtgg	gagaccataa
	721 tgtgtcagcc	accttgataa	atgacagggt	ggggaactgg	agggtngggg	gattgaaatg
	781 caagcaatta	gtggatcact	gttagggtaa	gggaatgtat	gtacacatct	attttttata
	841 cttttttttt	taaaaaagaa	tgctagttgt	tattttattca	aattatctca	cattatgtgt
	901 tcaacatttt	tatgtgtaag	tttcccttag	acattttatg	tcttgcttgt	agggcataat
	961 gccttggtta	atgtccattc	tcagcgtttt	ctctttccct	tggaagagag	aatttatcat
	1021 tactgttaca	ttgtacaaa	tgacatgata	ataaaagttt	tatg	

//

LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein;
 thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 from a human platelet-derived lambda gt11 expression library
 JOURNAL Blood 73 (6), 1498-1503 (1989)
 MEDLINE 89229374
 FEATURES Location/Qualifiers
 source 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gt11"
/map="4p13-q21"
gene      67..453
          /gene="PPBP"
sig_peptide 67..168
          /gene="PPBP"
          /note="G00-127-391"
CDS       67..453
          /gene="PPBP"
          /codon_start=1
          /db_xref="GDB:G00-127-391"
          /product="connective tissue activating peptide III"
          /db_xref="PID:g181176"

/translation="MSLRDTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN"

LAGKKEESLSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTNCNQVEVIATLKDGR
          KICLDPDAPRIKKIVQKLAGDESAD"
mat_peptide 196..450
          /gene="PPBP"
          /note="G00-127-391"
          /product="connective tissue activating peptide III"
mat_peptide 208..450
          /gene="PPBP"
          /note="G00-127-391"
          /product="beta-thromboglobulin"
polyA_site 673
          /gene="PPBP"
          /note="G00-127-391"
BASE COUNT      202 a      149 c      139 g      183 t
ORIGIN
    1 gggcaactca ccctcactca gaggtcttct ggttctggaa acaactctag ctcagccttc
   61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accacttcat
  121 gccttgcagg tgctgctgct tctgtcattg ctgctgactg ctctggcttc ctccacaaa
  181 ggacaaacta agagaaactt ggcgaaaggc aaagaggaaa gtctagacag tgacttgtat
  241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcattccaa aaacatccaa
  301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
  361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
  421 aaaaaattgg caggtgatga atctgctgat taattgttct tgtttctgcc aaacttcttt
  481 aactcccagg aagggtagaa tttgaaacc ttgattttct agagttctca tttattcagg
  541 atacctattc ttactgtatt aaaaatttga tatgtgttct attctgtctc aaaaatcaca
  601 ttttattctg agaaggttgg ttaaaagatg gcagaaagaa gatgaaaata aataagcctg
  661 gtttcaacc tct

//

LOCUS      HUMENA78A      2177 bp      DNA      PRI      31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
            complete cds.
ACCESSION  L37036 Z46254
NID        g607030
KEYWORDS   ENA-78 gene; homologue; neutrophil-activating factor;
            neutrophil-activating peptide 78.
SOURCE     Homo sapiens DNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2177)
AUTHORS    Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
            Strieter,R.M.
TITLE      Structure and neutrophil-activating properties of a novel
            inflammatory peptide (ENA-78) with homology to interleukin 8
JOURNAL    J. Exp. Med. 174 (6), 1355-1362 (1991)
MEDLINE    92078844
REFERENCE  2 (bases 1 to 2177)
AUTHORS    Walz,A.

```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher
 Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett,M.S., Schmitt,I., Riess,O. and Walz,A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791
 FEATURES
 source Location/Qualifiers
 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et
 al."
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

 /translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQGPPIASAGPAAAVL
 RELRCVCLQTTQGVHPKMISNLQVFAIGPOCSKVEVVASLKNQKEICLDPEAPFLKKV
 IQKILDGGNKEN"
 intron 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4
 BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN
 1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
 61 gtggtccttt caggccactg acttcaagtg gcaagagaca agggctctctt gttatcatgt
 121 tatcttggct tccaaagctg gttgaagtcc agagattcat aaagtcattc aagaaacctta
 181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
 241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
 301 caaatcaagg ctccctgttac tttggttcca ccttttctct ctagaaggag agggaggagca
 361 tctcccagat gctgcgtgct ccagaaaagc cggcatccct agcccgcctct ggcacaggcc
 421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
 481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctctctctgg
 541 ccacctctcc caccagtccc cattgtctgg ccccccctcc ccaacctctt ctttccacac
 601 tgcccatga gttcagggaa tttcccagc atcccaaagc ttgagtttcc tgtcagtggt
 661 gagagatgag tgtagataaa aggagtgcag aaggaaacgag gaagccacag tgctccggat

```

721 cctccaatct tcgctcctcc aatctccgct cctccacca gttcaggaac ccgcgaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcgcccc gtgtccccgg
841 tccttcgagc tccttggtgcg cgctgttggt gctgctgctg ctgctgacgc agccaggggc
901 catcgccagc ggtgagagcg catggcgcg cgacactcgg cgactcggg cacagagggtg
961 catcccagcc tctgcggggt cgctgcgttc cagggaactc tcccagcaac ctgccctata
1021 aaggggtgtct ctctttcttc cccagctgggt cctgccgctg ctgtgttgag agagctgcgt
1081 tgcgtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtgt
1141 ttgcccatag gccacacagt gctccaagggt gaagtgggtg aagtctctgt ctgctgtgtc
1201 cgctgtgacc ttggcaagag agaaatcccg cagcctgggt cttcaacctt ggtatctcat
1261 gagtgtatct tctttttctt tccttcagag cctccctgaa gaacgggaag gaaatttgtc
1321 ttgatccaga agcccccttt tcaaagaaag tcatccagaa aattttggac ggggtactgt
1381 cactttgatc tttgtggttt ctaaatctga tctagggaga ccatagactt cacaaggctt
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgtaatt
1501 gggaaaagtt ttctggattg tcctgggaaa atataccaat cttacatgta attacttgag
1561 caattacaca cagcttgtca ctaagttatg tttttgtttt acccattgct tttattgatt
1621 tttgtattct ctttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
1681 aaaggagtggt gaaaaatggt taaactaata taacattttt ctcaacagtg gaaacaagga
1741 aaactgatta agagaaatga gcacgcatgg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggagggt ctctgaaccc aggggaagaca agaaggaaag attttgttgt tgtttgttta
1861 tttgtttttc cagtagttag cttcttctct ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaataaa gtgttttagca tagtacctct
1981 gctatttgct gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccagggaat cactggcgtg taatctttca aagtgtcttg aattgtaggt gactattata
2101 tttccaagaa atattcctta agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

```

LOCUS       HSGCP2           254 bp      RNA              PRI          04-MAR-1997
DEFINITION  H.sapiens mRNA for granulocyte chemotactic protein.
ACCESSION   Y08770
NID         g1769436
KEYWORDS    cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte
            chemotactic protein.
SOURCE      human.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 254)
AUTHORS     Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A.,
            Wuyts,A.,
            Opdenakker,G., Van Damme,J. and Billiau,A.
TITLE       Cloning, bacterial expression and biological characterization
of          recombinant human granulocyte chemotactic protein-2 and
            differential expression of granulocyte chemotactic protein-2
and         epithelial cell-derived neutrophil activating peptide-78 mRNAs
JOURNAL     Eur. J. Biochem. 243 (3), 762-769 (1997)
MEDLINE     97210779
REFERENCE   2 (bases 1 to 254)
AUTHORS     Froyen,G.F.V.
TITLE       Direct Submission
JOURNAL     Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute,
University  of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
FEATURES    Location/Qualifiers
            source          1..254
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /haplotype="diploid"
                        /tissue_type="embryonic"
                        /rearranged
                        /cell_type="fibroblast"
                        /cell_line="E6SM (embryonic strain - skin and muscle)"
            gene            1..254
                        /gene="GCP-2"
            exon            <1..131
                        /gene="GCP-2"
                        /number=2
            CDS              <1..234
                        /gene="GCP-2"

```



```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKN"
    exon          132..215
                  /gene="GCP-2"
                  /number=3
    exon          216..254
                  /gene="GCP-2"
                  /number=4
    3'UTR         235..254
                  /gene="GCP-2"
BASE COUNT      66 a      64 c      70 g      54 t
ORIGIN
    1 ggtcctgtct ctgctgtgct cacggagctg cgttgcaactt gtttacgcgt tacgtgaga
   61 gtaaacccca aaacgattgg taaactgcag gtgttccccg caggcccgcga gtgctccaag
  121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggaccc ggaagcccct
  181 tttctaaaga aagtcattca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
  241 gtcgacgcgg ccgc

//

LOCUS      D63789      5669 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1beta precursor, complete cds.
ACCESSION  D63789
NID        g1754608
KEYWORDS   SCM-1beta; SCM-1beta precursor.
SOURCE     Homo sapiens placenta DNA, clone:hg44.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
            Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL    FEBS Lett. 360 (2), 155-159 (1995)
MEDLINE    95180438
REFERENCE  2 (sites)
AUTHORS    Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
            and Yoshie,O.
TITLE      Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
JOURNAL    FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE    97002294
REFERENCE  3 (bases 1 to 5669)
AUTHORS    Yoshida,T.
JOURNAL    Unpublished (1995)
REFERENCE  4 (bases 1 to 5669)
AUTHORS    Yoshida,T.
TITLE      Direct Submission
JOURNAL    Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya    Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima,   Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES   Location/Qualifiers
    source  1..5669
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /chromosome="1"
            /clone="hg44"
            /map="1q23"
            /tissue_type="placenta"
    TATA_signal  2154..2158
    exon        2197..2278

```

```

/number=1
prim_transcript 2197..5349
gene 2218..5230
/number=1
CDS join(2218..2278,4075..4189,5062..5230)
/number=1
/codon_start=1
/product="SCM-1beta precursor"
/db_xref="PID:d1010504"
/db_xref="PID:g1754609"

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRTCVSLTTQRLPVSRL
IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVVRSMDRKSNTRNNMIQTKPTGT
QQSTNTAVTLTG"
intron 2279..4074
/number=1
exon 4075..4189
/number=2
mat_peptide join(4077..4189,5062..5227)
/number=2
intron 4190..5061
/number=2
exon 5062..5349
/number=3
BASE COUNT 1702 a 1058 c 1248 g 1661 t
ORIGIN
1 ggatccagga ggataacaag ggaatctcct actctcaaag agtctgccat ctagtgggag
61 acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
121 acagaacaaa gttctaagag agcataaagg ggtggcacaa cttaatttta tcaaaaaaat
181 tcaggaaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
241 gtattccagt taaaggaaac atgtgaggag cataaaagag gctggcccat tgggttggct
301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatggtgga aggtgagtc
361 gaaaggaaaag cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaaat
421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaaat ggcattgata
481 gattgaggct ttacagtgtat taccctggca aagctgcaga gaacagactg agaggaggcc
541 ctgggtctggg taaccagtta gtccactgta atttgccata catttgagca gtgtggggag
601 aaaggaggag acatctcaaa ggactaccta gaagggtatac ttagtccagt ttggttgaga
661 atgacatgta ggtggatagc aatgagtgta agatgatccc tatatatcag tatttgaaaa
721 ttagatggaa gagaacacat tgcctcatgc taaggactaa tatgaggaga agcagtttga
781 atagaagatg tgtccagtgt tcaaggagtg attgtgcagt aaggtagaga tcattaaaga
841 gccagtttga agtttagaat gaagtctggg tgaataatca aatgcgatta gtgggaagtc
901 tcttagagggt taacctatac tttttatgaa aacataggaa tttattttca tattccctaa
961 tagcaaaagg cctttaacta cacatatatt taataaatac attttataga tacctatgta
1021 aaataaagaa caaccaccac acaacaaact cagtggcaga aaagtccag tgcaatcagt
1081 atattttaa tctactgggg gtattgcaaa tcaaatttac attttgggag ctatatggc
1141 aatatataat aagagctata aagatgatca tatcattttt cccagtaatc ctactcctgg
1201 ttattaaagg gaagtaattc agtgatatatt aatgaaatcg acctatagat tctgatcttt
1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
1321 tatgaaggct aaaaaaatgg gaagatatatt aaattgggtg taaaacagca tttaaaatta
1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
1441 aaactgtcag atggtaagat tataatttta tttctttttt aatttgaaat aaattggtaa
1501 cagcacagct tttcaaaagc ttctataaat gtgtatgtta agttgttaata aagcaaacac
1561 atgcatgtaa gacatgctta aacagttatt taattgtttc ttgggtacct ggggagatgg
1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaaatgagaa ccaagaaagc
1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gagtcaaagg
1741 gtggcatcag ggactcatga tccatgggtt tggaagcctc atgtcacact ggaatgcaca
1801 tgagggtggga tggaaacacag tgaccacccc acctcatttc cttacagct tccgtggggg
1861 ccatggcagt gaacagcctt caggcatgtc tacgggtgaa gatctgaatt caggctgggt
1921 gcaggagaca acacaaccac gttttctttt atgcatgcat ttggtttaat tgacacatta
1981 accacagaca aaggggtaaa gggcacaagg cgatagggtta gtatgaacag ggaaggggac
2041 attttttttt ttttaagaaa ataaaagcat cagtattgca aagactttcc atgatcctat
2101 acccacctcg aaagccccct ctcaccacag gaagtgcact gaccattgga ggcataaaag
2161 agactcctca agagcccgat cctcactctc cctgcacagc tcagcgggac ctcagccatg
2221 agactcttca tcttgccctc cctggccatc tgctctctca ctgcatacat tgtggaaggt
2281 aagtgagaaa gctgtctgtg agataaagaa tagggaggca aggcaggtgg gcacacattt
2341 tgggtttgac tgggtttttg actggactaa actgctgtct ccaggggagc cttaaacttc
2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaca

```

```

2461 gggagaattt gattagtatc tgggctccta ctttctctaä ttgggtaatt tcaggtaaat
2521 tcccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaagatta aataaatatt atgggttatt taataacatc agatttcctt
2641 acaagcagta attttttgat taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtagggtt ttgcccattt aatatatagt ttgataaatt atcaaatctt tagagagttc
2761 agttacaata tggggatgca ccagaggatg tatgttctgg agcaaatcaa tgttttcaat
2821 acaaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggatgtcc cagcttgcc
2881 ttccttcccc ttgataatgc aataagggac ccccatTTTA ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttggt
3001 ttccagcaag gtgggtgatga tgttaacccc tgctcaaaga acaggtgatt tcttagtggg
3061 gacaacccctt ttgctagcag ctttcttctc agcctgggcc aacagtctct ccttcttctc
3121 ttgctttgtc tctggtcagt acttgtggat cagcttaagt ggctgagtag ctgtttgggg
3181 gtctaaggct tgggtgaact ggtaaattggc agaaggcatt ttcaagctgt tatagaggat
3241 agctctttgc agctggaacc agatatagcg gggccatttc acaaacgagt ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct tttctcacac
3361 agcgggtttca tcactttctt agcctcctgc ttcctcacga cggcagggac tggggcacct
3421 tcttctcttt ggccttcttt ctttctcagc tcttaggcag ctgacagaga gggaaaattg
3481 accattttaa aaggggaaca cttttattta ctcagtcaaa agcatgcttc cttccctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca tatatggtag
3601 tgtaacatgt tgcactatgt gaaatgatct tttctgtttg cctgtctgct gcctggctcc
3661 ctcagtggaa gatattctct atgaaaacag ggataatgtc tgtcttaata aaacatgtgg
3721 gacacaacag gcaccattgt ataaatgaat gaatgcgtgt cactggggca tttgtagccc
3781 gtcccaaattg tctaagtga aatatacaca gagacgggat aacatcttgt tatcttctct
3841 cagcatgaaa ttcctgaaac aattctgttg attgagtttt taaattagtc aaatatctac
3901 taagaatctg tgacggggcaa gagattcggg atgectatca gtcctctctt cccccaaaa
3961 gcaaatggcc ttatatctct acaacattct cagagtaatt taacagacga ttgttctctg
4021 gatctgggta attgtcttat ttttaattgt ctgttgtttt ttttctctca tcagggttag
4081 ggagtgaagt ctcacatagg aggacctgtg tgacctcac taccagcga ctggcagtta
4141 gcgaatcaa gacctacacc atcacgggag gctccttag agcagtaagt tgagtctgcc
4201 tcttcagaag ttgggctggg tgggtaccta gaggtataga aatacactct atagaaatgc
4261 tgccatctct aggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaaagaa aatagaagtc ctcctctatt tgtcttagtg gaagagtctg
4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctggctca tgtcaggggt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatc
4561 tttactagtt gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcatTTTT agaagtaata actcttccca atacatattg caagctttgc
4681 tctaaagaat gaaaaatgta aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 tttgaaaagg aagaggttat ataataatgg aactagatgg cctcaaagt ctttttgtaa
4801 taacatttgg tgacatggat gagaaaagga gcctgtgaat tatgggtgaac aaagggctg
4861 gatactactt gcagatattt ctcctttatg ttaaaataga tggcagaaga aggggtgctc
4921 tttatgatct catggctctg aaagactatt tcttgcagta atttctgcac aagatctctt
4981 catgtctgce ctgatcttaa ctcctgacce tgaggctttg agaacgtggc taactctc
5041 tgtcttttcc ttgcgttaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
5101 acaagccacg tgggtgagag acgtggtcag gagcatggac aggaaatcca acaccagaaa
5161 taacatgatc cagaccaagc caacaggaac ccagcaatcg accaatacag cttgacacct
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttcacttta
5281 caccctcatg gactgagatt atactacct tttatgaaag cactgcatga ataaaattat
5341 tcttttgat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 ttatttatta ttaagaatag ttcctagtc tattcattat atttagggaa aggtagtgtg
5461 tcatgttgt ttgatttctg accttgtacc tctctttgat ggtaaccata atggaagaga
5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
5581 aatgggtctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

```

LOCUS      D63790      5660 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1alpha precursor, complete cds.
ACCESSION  D63790
NID        g1754610
KEYWORDS   SCM-1alpha precursor; SCM-1 alpha.
SOURCE     Homo sapiens placenta DNA, clone:hg40.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL    FEBS Lett. 360 (2), 155-159 (1995)

```

MEDLINE 95180438
REFERENCE 2 (sites)
AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
and Yoshie,O.
TITLE Structure and expression of two highly related genes encoding
SCM-1/human lymphotactin
JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE 97002294
REFERENCE 3 (bases 1 to 5660)
AUTHORS Yoshida,T.
JOURNAL Unpublished (1995)
REFERENCE 4 (bases 1 to 5660)
AUTHORS Yoshida,T.
TITLE Direct Submission
JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima, Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES Location/Qualifiers
source 1..5660
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/clone="hg40"
/map="1q23"
/tissue_type="placenta"
TATA_signal 640..644
exon 683..764
/number=1
prim_transcript 683..5340
CDS join(704..764,4064..4178,5053..5221)
/codon_start=1
/product="SCM-1alpha precursor"
/db_xref="PID:d1010505"
/db_xref="PID:g1754611"

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSRL
IKTYTITEGSLRAVIFITKRLKVCADPOATWVRDVVRSMRDKSNTRNNMIQTKPTGT
QQSTNTAVTLTG"
intron 765..4063
/number=1
exon 4064..4178
/number=2
mat_peptide join(4066..4178,5053..5218)
/note="SCM-1alpha mature peptide"
intron 4179..5052
/number=2
exon 5053..5340
/number=3
BASE COUNT 1623 a 1139 c 1175 g 1723 t
ORIGIN
1 aagcttctat aaatgtgtat gttaagtgtt aataaagcaa acacatgcat gtagacatgc
61 ttaaacagtt atttaattgt ttcttgggta cctggggaga tggggtgaag aaaggggggt
121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
181 agtgtggcag cagctctctt cccctcctga gagagtcaaa ggggtggcatc agggactcat
241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
301 agtgaccacc ccacctcatt tcctttacag cttccgtggt gggccatggc agtgaacacc
361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
541 agaaaaataa aagcatcagt attgcaaaga ctttccatga tcctacaccc acctcgaaag
601 cccctctca ccacaggaag tgcaactgacc actggaggca taaaagaggt cctcaaagag
661 cccgatcctc actctccttg cacagctcag caggacctca gccatgagac tctcatcct
721 ggcctctctt ggcattctgt ctctactgc atacattgtg gaaggtaagt ggagaagctg
781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg ttgtactcag
841 gttatgactg gactaatctg ctttcccatg gggagcctta aacttcccat gtgcaagaaa

901 ggaatgatga ttttgactgt agaggggttc gtaaaacttc aaaacagggg gaatttgatt
 961 agtatctggg ctctacttt tcctaattgg gtaatttcag gtaatttcct taaccactca
 1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
 1081 gattaaataa atattatggt ttatttaata acatcagatt tccttacaag cagtaatttt
 1141 ttgattaatg ttagctatgg attagagggt atgattataa atgcatttgt aggttttggc
 1201 catttaatat atagtttgat aaattatcaa aatcttagag agttcagtta cgatgtgggg
 1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
 1321 aaatgactgg aagttcaaac ctctatgtcc agaaaatcaa tattaccttc aagtaactgg
 1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaattttct gtttttgtaa
 1441 gagaacatac aataataact actaccaaag agatcagcac ctatatacaca gttcaataaa
 1501 cctgcaagac acatccaggt aagattcaga tataccgagc ccttacctga gcattcagta
 1561 ggtattttct aaggattgat ttttctatg actggagggt aatctgtcga ctattttgtg
 1621 tcttagttgg taggcttatt acctagacta tgatattata acttaataat gggtccccc
 1681 ggggttccat gaataaagggt ccctaagtct ggaagtcctt gaaattatgg ataaaaaaa
 1741 aaaatactga tgaacaaaa gagtttgatt actacattag gccacatgtt gctacctggc
 1801 tggcattttg ctgagacaa gggcatacca tttgagggag actcagatct gagtagggga
 1861 aaggagctct ataagttcca ctggtgctta gcttcttaca taaaaaaatc agggaaaaacg
 1921 gtctctgctt tgactcaatt ttgcaacctg agtgaagggt atatttttaa aaataacaca
 1981 gacactcaaa cattgctgac aataaggaaa aggtctttgt gtttcaagca taacaggatt
 2041 cctgagctct taggagttca ctccagatac ttccagagag gaaatattgt tctttaaata
 2101 tgagagaaac agagaaaaaa cccagatttt tctcttttca ttggctacag aaacaattca
 2161 ccactaaaaa taatttgcca aaggtagagg atagcaatgt gcagactggc attgagagtg
 2221 aagaaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
 2281 atgcttctg atattagcaa cactacagac caatgtttgg cattatcagt ggttacttta
 2341 gatgcttttt agctgcttat ttccctggga agcaaaagacc agtgtctaca gctaaggaga
 2401 aaatcagcac tttagaaactt ggattagatt tcaccaaaccc cttaacagta ttaattctcc
 2461 caagtatttt ttctcatgc aatgtttttt tgattctcta cacttaatag ttaattctct
 2521 ttggggccatt actattgggg atgcatattt aagggtgac ttctttttat atatatctta
 2581 ccttttacca ttatttaatt ttttggagag tttttattat ttttatgtac agaaaaactca
 2641 acagtgtaca ttaacccag ttttagtgga agttctcttg cctttgctat ttccagcttg
 2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
 2761 taattttgct tgatagcttc caccagctta gccaaagctc ctttgtcttc ctggttaact
 2821 tgtgtgaagg ccacagtggg gcttctcttg gactggatgt cccagctctg ccttcttacc
 2881 ccttgataat gcattaaggg accccccatt ttaggacaca ggacagacag aaagttaacc
 2941 agctttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
 3001 tgggtgatagt gttaaacctt gctcaaagaa cagggtgattt cctagtgggg acaacctctt
 3061 tgctagcagc ttcttctca gcttgggcca acagtctctg cttcttctct tgccttctct
 3121 ctgggtcagta cttgtggatc agcttaagtg gctgagtagc tgtttggggg tctaaggctt
 3181 ggggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
 3241 gctggaacca gatatagcgg ggcattttca caaagcagcg gaggctccct ttgggctgga
 3301 tgtcctgtcc aatgcctgcc taagaaaaact cttaggcctt ttctcacaca gcggtttcat
 3361 cactttctta gcctcctgct tcttcacgac ggcagggtct gggggcactt tcttctctt
 3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accatttaaa
 3481 aaggagaaaca cttttattta gtctgtcaaa agcatgcttc cttccctcac tgaatgttgc
 3541 ctgtcctaga gtactcttca cgcattactc tgccttctca ctatgggtact gtaacatgtt
 3601 gcaatatttg aaatgatctt ttctgtttgc ctgtctgctg cctggctctc tcatgagaga
 3661 gatattgctc atgaaaacag gagtaatgtc tgcttagtaa aacatgtggg acacaacagg
 3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagccg tcccaaatgt
 3781 ctaagtgaaa atatacacag agacgggata acatcttgtt attttctctc agcatgaaat
 3841 tcttgaaaca attctgttga ttgagttttt aaattagtc aatattttact aagaatctgt
 3901 gacgggcaag agattcggga tgcctatcag tctctcttcc ccccaaaaag caaatggcct
 3961 taaattctca caacattctc agagtaattt aacagatgat tgttctctgt atctggataa
 4021 ttgctttatt ttaattgtc tgttgttttt ttttctcac cagggttagg gagtgaagtc
 4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tgcgggttag cagaatcaag
 4141 acctacacca tcacggaagg ctctttgaga gcagtaatgt gagtctgcct ctcagaagt
 4201 tgtgctgggt gggatatctag aagtatagaa atacactctg tagaaatgct gccgtcctca
 4261 gggaaaagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
 4321 tctcaatca tgcctttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
 4381 caaagaaaga atagaagtcc tctctatttt agcttagtgg aagagtctgt tgaatactgt
 4441 gcacagctct gagacctggg tttagagatg actggcccat gtcagggttt ccttgcaagc
 4501 ctactggag ttgggggac tttaggttga gtcaggcaga gtcccatct tttatcagtt
 4561 gccatatttc aagaaaatga gtcaatgcac aacctacatg gtcccttctt ctaccagaat
 4621 ctcattttta gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaaa
 4681 tgaaaatgta aaaatcactt ttattttaaa aaataagatg aatattttta aatttgaaaa
 4741 ggaagaggtt atgtaataat ggaactagtt ggcctcaaag tctttttgtt acaacatttg
 4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggtc ggatactact
 4861 tgcagataat actcctttat gttaaaaatg atggcagaag aaggggtact atttatgac
 4921 tcatggctct gaaagactat ttcttgagc aatttctgca caagatctct tcatgtctgc
 4981 cctgacttca actcctgacc ctgaggtctt gagaatgtgg ctaactctgt ctgtcttttc
 5041 ctgtcggtac agttttatta ccaaacgtgg cctaaaagtc tgtgctgac cacaagcac
 5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataacatgat

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaataca gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 tttgatttct gaccttgtag ctctctttga tggtaaccat aatggaagag attctggcta
5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U91835
NID        g1899258
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute, 901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES
  source    Location/Qualifiers
            1..1635
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
  CDS       80..1273
            /note="membrane-tethered chemokine module"
            /codon_start=1
            /product="CX3C chemokine precursor"
            /db_xref="PID:g1899259"

/translation="MAPISLWLLRLATFCHLTVLLAGQHGVTKCNITCSKMTSKIP
VALLIHYQQNQASCGKRAIILETRQHRLFCADPKEQWVKDAMQHLDRQAAALTRNGGT
FEKQIGIEVKPRTTPAAGGMDESIVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
VTGSSGTRLPPTPKAQDGGFVGTLEFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
PSTQDPSTQASTASSPAPEENAPSEGQRVWGQGSPPRPNLSLEREEMGPVPAHTDAFQ
DWGPGSMAHVSVPVVSSEGTSPREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA
QAATRRQAVGLLAFLGLLFCLGVMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY
VLVPV"
  sig_peptide 80..151
  mat_peptide 152..1270
            /product="CX3C chemokine"
  misc_feature 152..379
            /note="encodes chemokine module"
  misc_feature 380..1102
            /note="encodes glycosylation stalk"
  misc_feature 1103..1159
            /note="encodes transmembrane helix"
  misc_feature 1160..1270
            /note="encodes intracellular domain"
  3'UTR       1274..1635
            /note="alternatively spliced; long transcript can be

```

found
in GenBank Accession Number U84487*

BASE COUNT	338 a	544 c	464 g	289 t			
ORIGIN	1	ggcagcaggg	cactgagctc	tgccgcctgg	ctctagccgc	ctgcctggcc	cccgcgggga
	61	ctcttgccca	ccctcagcca	tggctccgat	atctctgtcg	tggctgtccc	gcttgccac
	121	cttctgccc	ctgactgtcc	tgttggtg	acagcaccac	ggtgtgacga	aatgcaacat
	181	cacgtgcagc	aagatgacat	caaagatacc	tgtagctttg	ctcatccact	atcaacagaa
	241	ccaggcatca	tgcggcaaac	gcgaatcat	cttggagacg	agacagcaca	ggctgttctg
	301	tgccgaccgg	aaggagcaat	gggtcaagga	cgcgatgcag	catctggacc	gccaggctgc
	361	tgccctaact	cgaaatggcg	gcaccttcga	gaagcagatc	ggcgagggtga	agccaggac
	421	cacccttgcc	gccgggggaa	tggacgagtc	tgtggtcctg	gagccgaag	ccacaggcga
	481	aagcagtagc	ctggagccga	ctccttcttc	ccaggaagca	cagagggccc	tggggacctc
	541	cccagagctg	ccgacgggcg	tgactggttc	ctcagggacc	aggctcccc	cgacgcaaaa
	601	ggctcaggat	ggagggcctg	tgggcacgga	gcttttccga	gtgcctccc	tctccactgc
	661	cgccacgtgg	cagagtcttg	ctccccacca	acctggggccc	agcctctggg	ctgaggcaaaa
	721	gacctctgag	gccccgtcca	cccaggaccc	ctccaccag	gcctccactg	cgctctcccc
	781	agccccagag	gagaatgctc	cgtctgaagg	ccagcgtgtg	tggggtcagg	gacagagccc
	841	cagccagag	aactctcttg	agcgggagga	gatgggtccc	gtgccagcgc	acacggatgc
	901	cttcaggac	tgggggcttg	gcagcatggc	ccacgtctct	gtggtccctg	tctcctcaga
	961	agggaccccc	agcagggagc	cagtggcttc	aggcagctgg	acccctaagg	ctgaggaaacc
	1021	catccatgcc	accatggacc	cccagaggct	gggcgtcctt	atcactcctg	tccctgacgc
	1081	ccaggctgcc	accggaggcg	aggcgggtgg	gctgctggcc	tccctggccc	tcctctctg
	1141	cctgggggtg	gccatgttca	cctaccagag	cctccagggc	tgccctcgaa	agatggcagg
	1201	agagatggcg	gagggccttc	gctacatccc	ccggagctgt	ggtagtaatt	catatgtcct
	1261	ggtgcccgtg	tgaactcttc	tggcctgtgt	ctagttgttt	gattcagaca	gctgctggg
	1321	atccctcatc	ctcataccca	ccccaccca	agggcctggc	ctgagctggg	atgattggag
	1381	gggggaggtg	ggatcctcca	ggtgcacaag	ctccaagctc	ccaggcattc	cccaggaggc
	1441	cagccttgac	cattctccac	cttccaggga	cagagggggg	ggcctcccaa	ctcaccacag
	1501	ccccaaact	ctcctctgct	gctggctggg	tagaggttcc	ctttgacgcc	atccccagccc
	1561	caatgaacaa	ttattttatta	aatgcccagc	cccttctgaa	aaaaaaaaaa	aaaaaaaaaa
	1621	aaaaaaaaaa	aaaaaa				

//

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997
 DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
 complete cds.
 ACCESSION U84487
 NID g1888522
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
 Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE A new class of membrane-bound chemokine with a CX3C motif
 JOURNAL Nature 385 (6617), 640-644 (1997)
 MEDLINE 97177111
 REFERENCE 2 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
 Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research
 Institute,
 901 California Ave., Palo Alto, CA 94304-1104, USA
 FEATURES
 source Location/Qualifiers
 1..3310
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1888523"
 /translation="MAPISLSWLLRLATFCHLTVLLAGQHGVTRCNITCSKMTSKIP
 VALLIHYQQNQASCGKRAIILETRQHLFCADPKEQWVKDAMQHLDRQAAALTRNGGT"

FEKQIGEVKPRTPPAAGMDESIVLEPEATGESSSLEPTSSQEAQRALGTSPELPTG

VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSPAPEENAPSEGQRVWVGQGSPPRPNLSLREEMGPVPAHTDAFQ

DWGPGSMAHVSVPVSSEGTSPREPVASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLGLFLCLGVAMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY

VLVPV"

sig_peptide 80..151

mat_peptide 152..1270

/product="CX3C chemokine"

misc_feature 152..379

/note="encodes chemokine module"

misc_feature 380..1102

/note="encodes glycosylation stalk"

misc_feature 1103..1159

/note="encodes transmembrane helix"

misc_feature 1160..1270

/note="encodes intracellular domain"

3'UTR 1274..3310

/note="alternatively spliced; short transcript

deposited

as GenBank Accession Number U91835"

BASE COUNT 659 a 1051 c 916 g 682 t 2 others

ORIGIN

```

1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgctgggcc cccgccggga
61 ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 ctcttgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
241 ccaggcatca tgccggcaaac ggcgaatcat cttggagacg agacagcaca ggctgttctg
301 tgccgacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tgccctaact cgaaatggcg gcaccttoga gaagcagatc ggcgaggtga agcccaggac
421 caccctgccc gccgggggaa tggacgagtc tgtggtcctg gagcccgaag ccacaggcga
481 aagcagtagc ctggagccga ctcttcttcc ccaggaagca cagagggccc tggggacctc
541 cccagagctg ccgacgggag tgactggttc ctacgggacc aggcctcccc cgacgccaaa
601 ggctcaggat ggagggcctg tgggcacgga gcttttccga gtgcctcccc tctccactgc
661 cgccacgtgg cagagttctg ctccccacca acctgggccc agcctctggg ctgaggcaaa
721 gacctctgag gccccgtcca cccaggaccc ctccaccagg gcctccactg cgtcctcccc
781 agccccagag gagaatgtct cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 cagggcagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 ctccaggac tgggggcctg gcagcatggc ccacgtctct gtgggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaacc
1021 catccatgcc accatggacc cccagaggct gggcgtctct atcactctctg tccctgacgc
1081 ccaggctgcc acccggaggc aggcggtggg gctgctggcc ttccttggcc tctctctctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgccctcga agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactcttc tggcctgtgt ctagtgtgtt gattcagaca gctgctggg
1321 atccctcatc ctcatacca cccccacca agggcctggc ctgagctggg atgattggag
1381 gggggagggt ggatcctcca ggtgcacaag ctccaagctc ccaggcatte cccaggaggc
1441 cagccttgac cattctccac ctccaggga cagagggggg ggcctcccaa ctacccccag
1501 ccccaaaact ctctctgtg gctggctggt tagaggttcc ctctgacgac atccccagcc
1561 caatgaacaa ttatttatta aatgccacgc cccttctgac ccatgctgcc ctgtgagtac
1621 tacagtcttc ccatctcaca catgagcatc aggcagggcc ctctgcccac tccctgcaac
1681 ctgattgtgt ctcttggtcc tgctgcagtt gccagtcacc ccggccacct gcggtgctat
1741 ctccccagc cccatcctct gtacagagcc cagccccca ctgggtgacat gtcttttctt
1801 gcatgaggct agtgtgtgt ttcctgggca ctgcttccag tgaggctctg cccttgggta
1861 ggsattgtgg gaaggggaga taagggtatc tgggtgacttt cctcttgggt ctacactgtg
1921 ctgagctctga aggtgggtt ctgatcctag ttccaccatc aagccaccaa catactccca
1981 tctgtgaaag gaaagaggga ggtaaagaa acctgtcccc ctgacaacac tcatgtacct
2041 gaggccttc tctccagccc ctggatgcag cctcacagtc cttaccagca gagcactta
2101 gacagtcctt gccaatggac taacttgtct ttggaccctg aggcaccagag ggctgcarg
2161 ggagtgaagt gatagcacag accctgccct gtgggcccc aaatggaaat gggcagagca
2221 gagaccatcc ctgaaggccc cgcccaggct tagtactga gacagcccgg gctctgctc
2281 ccatcacccg ctaagaggga gggagggttc cagacacatg tccaagaagc ccaggaaagg
2341 ctccaggagc agccacattc ctgatgtctc ttcagagact cctgcaggca gccaggccac
2401 aagacccttg tgggtccacc ccacacagc cagattcttt cctgaggctg ggctccttc
2461 ccacctctct cactccttga aaacactgtt ctctgcccc caagaccttc tcttccact
2521 ttgtcccccac cgcagacagg accaggggat ttccatgatg ttttccatga gtcccttgtt
2581 tgtttctgaa agggacgcta cccgggaagg gggctgggac atgggaaagg ggaagtgtga

```



```

2641 ggcatataaagt caggggttcc cttttttggc tgctgaaggg tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggca gctcacctct cccttggatt
2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ctttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctcaggtggg gtcactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gagcctttca
3061 ggggtgggac accctgtgat ggggccctgc ctcctttgtg aggaagccgc tggggccagt
3121 tgggtccccc tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact tttccaaccc tcatcaccaa
3241 cgtctgtgcc attttgtatt ttactaataa aattttaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
            cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /chromosome="17"
            gene           1..1430
                           /gene="HCC-4"
            CDS            1..363
                           /gene="HCC-4"
                           /note="CC or beta chemokine family member"
                           /codon_start=1
                           /product="IL-10-inducible chemokine"
                           /db_xref="PID:g2581781"

/translation="MKVSEAAALSLVLILITTSASRSQPKVPEWVNTPTCCLKYYEK
VLPRRLVVGYRKALNCHLPAIIFVTKRNRREVCTNPNDWVQEIYKDPNLPPLPTRNLS
TVKIITAKNGQPQLLSQ"
BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN
1 atgaaggtct ccgaggtctc cctgtctctc cttgtctctc tccttatcat tacttcggct
61 tctgcagacc agccaaaagt tcctgaggtg gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtggtgggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgtgtgc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattagtc tgaaactagc cagtccattt gagagaagca gaacaatgat
481 caaaataaaag gagaagtatt tcgaatattt tctcaatctt aggaggaagt accaaagtta
541 agggacgtgg gcagagggtc gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcaccg aggtctggag gcagtggtgt gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgtatc tcccaccca gccctccgag
721 tagctgggac tacaggcttg cgccaccaca cctggctaat tttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggt taaaactcgt gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtcg tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctctct ctctctttca attcctcact

```

```
961 tcacaccagt acacaagcca ttctaataac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatfff tcctgtccat
1081 ctttatggat ttttctggat ctatatattc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa
```

//

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.